annual report caring world one person time inspires unites people johnson johnson onthecover michelleanemployeewiththejohnsonjohnsonfamilyof scan thisqr code toview companiesenjoystimewithheryoungdaughteralexiswhile adigital version grandmotherjacquelinelooksonjohnsonjohnsonhelpspeople johnson johnson annual report allovertheworldcareforthehealthandwellbeingofthosethey loveandtolivelongerhealthierhappierliveschairmans letter shareholders sibegantocomposethisletterirealizedhowquicklymyfirstyearhas passedaschiefexecutiveofficerofjohnsonjohnsonithasbeena yearwithmanyrewardingmomentsaswellassomechallengesthough ayearoftransitionwemadesolidprogressonmanyfrontsincluding buildingoutstrategicplatformswhileestablishingexcitingnewones iamhonoredtobejusttheseventhceoinourlonghistorythislegacyof leadershipisatributetothesuccessandstabilityofjohnsonjohnsonandtothe beliefintheimportanceofourpurposeheldincommonwithusbyourshareholders oversomanydecadespersonallyiamtrulyhumbledtoleadtheincrediblytalented anddedicatedpeoplewhoworkforjohnsonjohnson onechallengeallofusintheworldtodayfacetogetherishealthandhealthcare thisistrueinbothdevelopedandemergingmarketswhencombinedwiththe rapidlychangingdemographicsofanagingpopulationagrowingmiddleclassand thepersistenceofchronicdiseasethescaleandcomplexityoftheissueismagnified itismybeliefthatprovidinghighqualityhealthcaretopatientsandconsumers alexgorsky aroundtheworldinasustainablemannerissocietysgreatestchallengebutitisalso chairmanboardofdirectorsand thegreatesthopeforabetterfutureforeveryindividualeveryfamilyevery chiefexecutiveofficer communityandeverycountry johnsonjohnsonworksattheverycenterofthischallengeacrossthebroadestbaseofanycompanyinglobalhealthcareevery dayweareworkingtohelppeopleeverywherelivelongerhealthierandhappierliveswerecognizethatwithourgloballeadership comesaresponsibilityoneweconsideraprivilegeimpleasedwithhowwearemeetingthatresponsibilitybutimfarfromsatisfied thepassinglastfallofformerceojamesburkeremindedusallthatthesimplesetofbeliefsdefinedinourcredocanguideour companythroughallthechallengesandcomplexitiesoftheseoranytimemyoverarchinggoalasceoistoensurethatournearly employeesinmorethanoperatingcompaniesaroundtheworldwillalwaysbeunitedbyourcredoandoursingle purposecaringfortheworldonepersonatatime legacyofcaring thatpurposewasatworkhereinnewjerseythehomestateofjohnsonjohnsonwhenhurricanesandyroaredthroughsomany communitieslastyearimmediatelypartneringwiththeamericanredcrosssavethechildrenamericaresandotherdisaster assistancegroupsjohnsonjohnsonwasabletohelpprovideaidandreliefweprovidedmorethanfirstaidkitsthatwere usedbyemergencyrespondersweprovidedtheblanketsthatwarmedfamiliesinsheltersweweretherewithmorethanmillion infundingrespondingtothegovernorsofthreestatesinthisregionmostimportantlyourpeoplewerethereintheirown communitiesimmediatelyandwithouthesitationtheywereonthefrontlinesofresponseandreliefeffortswhereverandhowever theycould itisthisexampleofcaringbyindividualsthatinspirescaringinthewholecommunityandremindsmeofhowfirmlyand fundamentallycompassioniswovenintothefabricofourculturethislegacyofcaringcontinuesaswerenewourcommitmentto philanthropyandcitizenshipallovertheworldwewilllooktogobeyondreliefandrebuildingandexploreprogramsthatwillmake communitiesmoreresilientandpreparethemtoendureanykindofdisasterbeitnaturaloreconomic businessresults oursolidbusinessresultsinwereachievedwhilecontinuingtodelivermeaningfulinnovationinhealthcaretopatientsand customers wegeneratedsignificantcashflowandmaintainedouraaacreditratingimportantlywecontinuedourtrackrecordof consistentperformancewithstraightyearsofadjustedearningsincreasesandconsecutiveyearsofdividendincreases johnsonjohnsonisoneofonlysixcompaniesinthestandardpoorsindextoachievethatrecord inourpharmaceuticalsbusinesssegmentourresultsincludedstronggrowthofkeyproductsandsuccessfulnewlaunches asaresultofourcontinuingcommitmenttoresearchanddevelopmentcollaborationandinnovationweexpectto maintainstrongmomentumwecontinuetomakeimportantinvestmentsinbuildingstrategicpartnershipsandadvancing ourpipelinepositioninguswelltodeliversustainablegrowthinandbeyond chairmansletter theadditionofsynthesinctoourfamilyofcompaniesmarkedthelargestacquisitioninourhistoryandcombined withdepuycreatestheworldslargestmostcomprehensiveorthopaedicsandneurologicsbusinessthedepuysynthes companieswewillcontinuetheexcitingintegrationofsynthesintoourmedicaldevicesanddiagnosticsbusiness segmentinthecomingyear inourconsumerbusinesssegmentwewillcontinuerestoringareliablesupplyofourmcneiloverthecounter medicinestheworktobringourplantsfullyonlineisprogressingweexpecttoreturnaconsistentsupplyofkey productstothemarketoverthecourseofwearedefinitelymakinggoodprogresshoweverwemustmovefrom goodtogreatthisyear moredetailsontheprogressofourthreebusinesssegmentscanbefoundinthebusinesssegmenthighlightssectionofthis annualreport ensuringrobustgrowth withinthecontextofourcredoandstrategicframeworktherearespecificareasoffocusforjohnsonjohnsonourgrowth driversthatwillhelpensurerobustgrowthforthefuture firstisourcommitmenttoinnovationtocreatevaluenotjustinnovationinproductsandservicesbutineverythingwe doandeverywhereweoperateweneedaconstantflowofnewideasanddifferentapproachestomeetthechallengesand opportunitiesofthefuture secondourglobalreachmustbebroughttolifewithalocalfocusthatputscriticaldecisionmakingwheretheneedsare andwhereourglobalresourceslivewebelieveourcommitmenttodecentralizedmanagementprovidesacompetitive advantageinallofourbusinessesandallofourmarkets thirdwewillhavealaserfocusonexcellenceinexecutionacrossourenterprisewehavebuiltgreateraccountabilityfor qualityintotherequirementsforallofourleadersthishasstrengthenedqualityandcomplianceattheenterpriselevelby takingspecificstepstoreducevariationandincreasegovernanceweveredefinedstandardsandprocessesinoursupply chaintomostimportantlyimprovethelevelofexecutionandtodeliverefficienciesthatcanfreeresourcesfor investment fourthwewillcontinuetofosterapurposedrivenorganizationanddevelopleadershipateverylevelofourcompany thisisessentialforustodeliverontheresponsibilitiesthatcomealongwithourgloballeadership addressingaglobalchallenge ourbroadbaseinhealthcaregivesusauniqueperspectiveontheneedsfearsfrustrationsandhopesofconsumerspatientstheir familiesandhealthprofessionalsworldwideibelievethatahealthierworldisnotjustahappierworldbutalsoonethathasmuch greatereconomicstabilityandprovidesafoundationforindividualandsocietaladvancementimveryproudoftheprogresswe havemadetowardourpurposeofcaringfortheworldonepersonatatimebutallofusarekeenlyawareofthegapsthatstillexist intheworld forexamplethereisagapinaccesstobasichealthcarewhetherbecauseofalackoftrainedprofessionalsinadequate infrastructureorculturalobstaclesaddressingthisgapisakeylongtermgoalforusastheleaderinglobalhealthcare thereisagapinadequatementalhealthcareservicesthishascometopublicattentioninglaringexamplesofrecenttragediesin theunitedstatesagainthisgapmaybearesultofalackoftrainedprofessionalsorthestigmathattoooftenpreventspeoplefrom seekinghelp thereisagapinpreventivemedicinethatoftenfocusessocietiesonsickcareratherthanhealthcarethisisaparticularfocus formeandforallofusatjohnsonjohnsonnotonlybecauseofthedepthoftheproblembutalsobecauseofthescopeofthe opportunity canweclosethesegapswearecommittedtoconveningadialoguethatrecognizesandaddressesthesesignificantgapsin caringwewillworkwithcommunitiesandlocalpartnersaroundtheworldtotakemeaningfulactiontoimprovepeopleslives thatsaglobalchallengeweaimtoaddressworkingtogetherwecanandwemust ourinspiration thechallengeswefaceinthiseverchanginghealthcarelandscapewillrequiretimevigilanceanddedicationtosolveallofushere atjohnsonjohnsonrealizeweareonajourneyeverydaythoughiaminspiredbyyetanotherstoryofhowwehavedeliveredon ourcredo johnsonjohnsonannualreportthisyearwevecreatedafullyinteractivedigitalonlineannualreportwhereyoucanfindourstoriesofcaringhereareafew examplestogiveyouanideaofthebreadthofthismosaic ashaisamotherraisingchildreninbangladeshwherereliablehealthinformationcansometimesbehardtofindafter strugglingwiththehealthofherfirstchildashaisnowbetterpreparedtotakecareofhernewdaughterthankstovital healthmessagesdeliveredbytexttohermobilephonejohnsonjohnsonandbabycenter arefoundingpartnersina uniquecollaborationtoimprovethelivesofpregnantwomennewmothersandtheirfamiliesindevelopingcountries forbillreachinghisthbirthdaywasmorethanamilestoneafteradiagnosisofprostatecancerseveralyearsagoanda seriesoftreatmentshedidntknowwhatwouldlieaheadnowhesonzytiga abirateroneacetateandhes spendingcherishedtimewiththepeoplehelovesandtrulycelebratingthatthbirthday braydonisanormalteenagerinmanywayshelovestohangoutwithhisfriendsplaygolfdoworkwithhisdadallthis despitebeingbornwithseverescoliosisthatcausedhisspinetocurvefusedhisribsandthreatenedtoleavehim wheelchairboundandunabletobreathewithouthelpthankstotheinnovativeveptr procedurefromdepuy synthesspinebraydoncangoaboutlivinglifetothefullest youcanfindtheseandotherstoriesofcaringaswellasmuchmoreatwwwannualreportjnjcomihopeyoulllikethese storiessomuchthatyoulldecidetosharethemandourdigitalannualreportwithfamilyandfriends mycommitmenttoyou ourleadershipinhealthcarehasbeenmadepossiblebythebeliefinourmissionthatyousharewithusiamcommittedto continuingtheproudtraditionofjohnsonjohnsonasapurposeledorganizationcallingonthegreatrangeanddiversityofour worldwidetalentandcapabilitieswewillfurtherdedicateourselveseverydaytotheresponsibilitiesdefinedinourcredothefirst beingourresponsibilitytothedoctorsnursesandpatientsthemothersandfathersandallwhouseourproductseverydaywell alsocontinueourcommitmenttoouremployeesandtothecommunitiesinwhichweoperateandproudlycallhomeandtoyou ourvaluedshareholderswhohaveplaceyourconfidenceandtrustinus thisisourlegacyatjohnsonjohnsonatlastyearsannualshareholdermeetingidescribedmyselfasarealisticoptimistand despiteourchallengesifirmlybelievethereisnocompanybetterpositionedtoberecognizedastheworldsleaderinhealthcare sincerely alexgorsky chairmanboardofdirectorsandchiefexecutiveofficer march excludesspecialitems chairmansletter business segment highlights johnsonjohnsondeliveredsolidresultsinreflectingcontinuedsalesmomentuminmanypartsofourbusiness drivenbyourfocusondeliveringmeaningfulinnovationinhealthcaretopatientsandcustomersourresultsincluded stronggrowthofkeyproductssuccessfulnewproductlaunchesandtheadditionofsynthestoourfamilyofcompanies inadditionwecontinuedtomakeimportantinvestmentsbuildingstrategicpartnershipsandinadvancingourpipeline positioninguswellfordeliveringsustainablegrowth pharmaceutical segment sales medical devices diagnostics consumer segment sales sales therapeutic area billions dollars segment sales sales major franchise billions dollars sales billion sales major franchise billions dollars sales billion sales change sales billion sales change total sales change total operational total operational h er operational vi io n care card c v aa r ecular womens health wo u n h ec rare b b ca r e oncology surgical care diabetes care oral care imm u n logy diagnostics neu r os c ience speci l ty surgery k c previennfteciotnioont otc infect u diseases ort h p edics nu r io nals operational excludes impact currency excluding net impact synthes acquisition mdd rounded visual accuracy total change orthopaedics total change pharmaceuticals withbillioninworldwidesalesinwearetheeighthlargestpharmaceuticalsbusinessintheworldandthe sixthlargestbiotechbusinessprimarycontributorstostrongoperationalgrowthofpercentincluderemicade infliximababiologicapprovedforthetreatmentofanumberofimmunemediatedinflammatorydiseases velcade bortezomibatreatmentformultiplemyelomaprezista darunaviratreatmentforhivanda numberofrecentlylaunchedproducts weareacceleratinggrowthwhileensuringgreateraccessandreimbursementbyimplementingstronglaunch programsforrecentlyapprovedproductsincludingzytiga abirateroneacetateanoraloncedailymedicationfor useincombinationwithprednisoneforthetreatmentofmetastaticcastrationresistantprostatecancerinvega sustenna xeplion paliperidonepalmitateaoncemonthlylongactinginjectableatypicalantipsychoticfor treatmentofschizophreniainadultsincivo telapreviradirectactingantiviralproteaseinhibitorforthetreatment ofgenotypechronichepatitiscvirusincombinationwithpeginterferonalfaandribavirininadultsstelara ustekinumababiologicapprovedforthetreatmentofadultswithmoderatetosevereplaquepsoriasisxarelto rivaroxabananoralanticoagulantandsimponi golimumababiologicapprovedtotreatadultswithmoderately toseverelyactiverheumatoidarthritisraactivepsoriaticarthritisandactiveankylosingspondylitis business segmenthighlights salesresultswerenegativelyimpactedbygenericcompetitionforlevaquin levofloxacinatreatmentfor bacterialinfectionsandthemanufacturingsuspensionatathirdpartysupplierfordoxil doxorubicinhcl liposomeinjectioncaelyx pegylatedliposomaldoxorubicinhydrochlorideamedicationtotreatovarian andothercancers indecembertheusfoodanddrugadministrationfdagrantedacceleratedapprovalforsirturo bedaquilinetabletsforthetreatmentofpulmonarymultidrugresistanttuberculosisaspartofcombinationtherapy inadultsitiscurrentlyunderreviewbythreeregulatorybodiesincludingtheeuropeanmedicinesagencyeustate foodanddrugadministrationchinaandmedicinescontrolcouncilsouthafricathefdaandtheeuropean commissionalsoapprovedanexpandedindicationforzytiga abirateroneacetateincombinationwith prednisoneallowingfortheusebeforechemotherapyinthetreatmentofmetastaticcastrationresistantdisease innovemberthefdaapprovedadditionalindicationsforxarelto rivaroxabanforthetreatmentofdeep veinthrombosisdvtandorpulmonaryembolismpeandtoreducetheriskofrecurrenceofdvtandpe followinginitialtreatmentinadditionthefdaapprovedanewmgtabletofprezista darunavirfor oncedailyoraladministrationforthetreatmentofhumanimmunodeficiencyvirushivintreatmentnaive andtreatmentexperiencedadultpatientswithnodarunavirresistanceassociatedmutations inaugustthefdaapprovedthesupplementalnewdrugapplicationfornucynta ertapentadol extendedreleasetabletsforthemanagementofneuropathicpainassociatedwithdiabeticperipheralneuropathy inadultsinseptembertheeuropeancommissionapprovedthemarketingauthorizationfordacogen decitabineforthetreatmentofadultpatientsageyearsandabovewithnewlydiagnoseddenovoor secondaryacutemyeloidleukemiaandforthesubcutaneousadministrationofvelcade bortezomibforthe treatmentofmultiplemyeloma wehaveanexcitingandlatestagepipelineofdifferentiatedmedicinesnewdrugapplicationsarepresently underreviewintheunitedstatesandintheeuropeanunionseekingapprovalforinvokanacanagliflozin ourfirstpharmaceuticaltreatmentforpatientswithtypediabetesadditionalsubmissionsincludeda supplementalbiologicslicenseapplicationtothefdaandatypeiivariationtotheeuropeanmedicines agencyrequestingapprovalofstelara ustekinumabforthetreatmentofadultswithactivepsoriaticarthritis andofsimponi golimumabforthetreatmentofadultswithmoderatelytoseverelyactiveulcerativecolitisa biologicslicenseapplicationwasalsosubmittedtothefdaseekingapprovalofintravenousivgolimumab forthetreatmentofmoderatelytoseverelyactivera proposedtradename medicaldevicesanddiagnostics withbillioninworldwidesalesinourmedicaldevicesanddiagnosticsmddbusinessisthelargest medicaltechnologybusinessintheworldoperationalgrowthwaspercentsalesincludedtheimpactofthe recentlycompletedacquisitionofsynthesincwhichcontributedpercenttoworldwidemddsegment operationalsalesgrowthnetofthedivestitureofthedepuytraumabusinessprimarycontributorstooperational growthweresalesfromtherecentlycompletedacquisitionofsynthesincintheorthopaedicsbusinessanumberof productsinthespecialtysurgerybusinesselectrophysiologyproductsinthecardiovascularcarebusinessof biosensewebsterincdisposablecontactlensesfromvistakondivisionofjohnsonjohnsonvisioncareinc whileoverallmarketgrowthhasslowedwevebeenfocusingonbuildingourmarketleadershippositionand weholdnoornopositionsinpercentofourkeyplatforms wecontinuetoinvestforlongtermsustainablegrowthandcompletedthelargestacquisitioninourhistory withsynthesinjunedepuyandsynthesjoinedtoformtheworldslargestmostcomprehensiveorthopaedics andneurologicsorganizationatotalsolutionsbusinessdepuysynthesoffersanunparalleledbreadthanddepth ofproductsservicesandprogramsintheareasofjointreconstructiontraumaspinesportsmedicine neurologicalcraniomaxillofacialpowertoolsandbiomaterialsandhastheopportunitytocontributeingreater waystomeettheneedsoftodaysdynamichealthcareenvironment inthefdaapprovedevarrest fibrinsealantpatchanovelproductthatrapidlyandreliablyaidsin stoppingproblematicbleedingduringsurgerythefdaalsoapprovedthesmart control vascular stentsystemsforuseinthesuperficialfemoralarteryandortheproximalpoplitealarterytheharmonic ace shearswithadaptivetissuetechnologystrengtheningourpositioninthefastgrowingenergymarket wasalsoapprovedbythefdain johnsonjohnson annual report earlierintheyearethiconendosurgeryincreceivedanapprovableletterforthesedasys systema computerassistedpersonalizedsedationsystemfromthefdascenterfordevicesandradiologicalhealthin additionbiosensewebstersthermocool smarttouch contactforcesensingcatheterreceivedce markclearanceineuropethecatheterprovidesrealtimeinformationaboutthepreciseamountanddirectionof theforcebeingappliedduringcardiacablationprocedures wereexpandingourglobalpresencewithstronggrowthinemergingmarketsandaswelooktothefuture wereadvancinginnovativenewproductsinourpipelinecontinuingtotakeadisciplinedapproachtomanaging ourportfolioandadaptingourbusinesstothechangingmarketplace consumer withbillioninworldwidesalesinourconsumerbusinessisthesixthlargestconsumerhealthcare businessintheworldoperationalgrowthwaspercentweremaincommittedtostrengtheningtheconsumer businessstartingbycontinuingtorestoreareliablesupplyofourmcneiloverthecounterotcproductstothe usmarket meanwhilepositivecontributorstooperationalresultsweresalesofupperrespiratoryotcproductsoutside theusinternationalsalesoflisterine oralcareproductsandussalesofneutrogena skincare products ourinvestmentsforgrowthinconsumerwillbepredicatedonafocusedproductportfolioapproachtodeliver sciencebasedproductswithlocalmarketinsightsprofessionalendorsementsandcommercialexcellence wehavetakenstepstoreshapeourportfolioandhavedivestednonstrategicproductsorbrandswearealso investingingrowthandexpansioninemergingmarketsthroughtheacquisitionofmarketspecificbrandslike doktormom coughcoldproductsinrussiaandshanghaielskermotherbabycoltdinchinawere alsocontinuingtoleveragethestrengthofouriconicbrandslikejohnsons babyandneutrogena regardingmcneilwerecontinuingtooperateinaccordancewiththeconsentdecreeweveachievedall commitmentstodateundertheremediationworkplanwhichwasapprovedbythefdaintheworkto bringourplantsfullyonlineisprogressingweexpecttoreturntoaconsistentsupplyofkeyproductstothe marketoverthecourseofoureffortscontinuetobeintheinterestofservingcustomersconsistentwiththe responsibilitiesoutlinedinourcredo noteonforwardlookingstatements thisannualreportcontainsforwardlookingstatementsasdefinedintheprivatesecuritieslitigationreformactof thereaderiscautionednottorelyontheseforwardlookingstatementsthesestatementsarebasedoncurrentexpectationsof futureeventsifunderlyingassumptionsproveinaccurateorunknownrisksoruncertaintiesmaterializeactualresultscould varymateriallyfromtheexpectationsandprojectionsofjohnsonjohnsonrisksanduncertaintiesincludebutarenotlimited togeneralindustryconditionsandcompetitioneconomicfactorssuchasinterestrateandcurrencyexchangeratefluctuations technologicaladvancesnewproductsandpatentsattainedbycompetitorschallengesinherentinnewproductdevelopment includingobtainingregulatoryapprovalssignificantadverselitigationorgovernmentactionimpactofbusinesscombinations changesinbehaviorandspendingpatternsorfinancialdistressofpurchasersofhealthcareproductsandserviceschangesto governmentallawsandregulationsanddomesticandforeignhealthcarereformstrendstowardhealthcarecostcontainment increasedscrutinyofthehealthcareindustrybygovernmentagenciesmanufacturingdifficultiesordelaysandproductefficacy orsafetyconcernsresultinginproductrecallsorregulatoryactionafurtherlistanddescriptionoftheserisksuncertaintiesand otherfactorscanbefoundinexhibitofjohnsonjohnsonsannualreportonformkforthefiscalyearended decembercopiesofthisformkaswellassubsequentfilingsareavailableonlineatwwwsecgov wwwinvestorjnjcomoronrequestfromjohnsonjohnsonjohnsonjohnsondoesnotundertaketoupdateany forwardlookingstatementsasaresultofnewinformationorfutureeventsordevelopments business segmenthighlightsmanagementsdiscussionandanalysis ofresults ofoperationsandfinancialcondition organizationandbusinesssegments resultsofoperations analysisofsalesbybusinesssegments analysisofconsolidatedearningsbeforeprovisionfortaxesonincome liquidityandcapitalresources otherinformation cautionaryfactorsthatmayaffectfutureresults auditedconsolidatedfinancialstatements consolidatedbalancesheets consolidatedstatementsofearnings consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflows notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporting supportingschedules summaryofoperationsandstatisticaldata shareholderreturnperformancegraphs johnsonjohnsonannualreport managements discussion analysis results operations financial condition organization business segments descriptionofthecompanyandbusinesssegments johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesand diagnosticstheconsumersegmentincludesabroadrangeofproductsusedinthebabycareskincareoralcare woundcareandwomenshealthfieldsaswellasnutritionalandoverthecounterpharmaceuticalproductsandwellness andpreventionplatformstheseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutletsand distributorsthroughouttheworldthepharmaceuticalsegmentincludesproductsinthefollowingareasantiinfective antipsychoticcontraceptivegastrointestinalhematologyimmunologyinfectiousdiseasesneurologyoncologypain managementthrombosisandvaccinestheseproductsaredistributeddirectlytoretailerswholesalersandhealthcare professionalsforprescriptionusethemedicaldevicesanddiagnosticssegmentincludesabroadrangeofproducts distributedtowholesalershospitalsandretailersusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitals andclinicstheseincludeproductstotreatcardiovasculardiseaseorthopaedicandneurologicalproductsbloodglucose monitoringandinsulindeliveryproductsgeneralsurgerybiosurgicalandenergyproductsprofessionaldiagnostic productsinfectionpreventionproductsanddisposablecontactlenses thecompanysstructureisbasedupontheprincipleofdecentralizedmanagementtheexecutivecommitteeof johnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategicoperationsandallocationofthe resourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesoftheconsumerpharmaceuticaland medicaldevicesanddiagnosticsbusinesssegments inallofitsproductlinesthecompanycompeteswithcompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsisimportanttothecompanyssuccessinall areasofitsbusinessthisalsoincludesprotectingthecompanysportfolioofintellectualpropertythecompetitive environmentrequiressubstantialinvestmentsincontinuingresearchandinmaintainingsalesforcesinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificant expendituresforadvertisingandpromotion managementsobjectives thecompanymanageswithinastrategicframeworkaimedatachievingsustainablegrowthtoaccomplishthisthe companysmanagementoperatesthebusinessconsistentwithcertainstrategicprinciplesthathaveprovensuccessful overtimetothisendthecompanyparticipatesingrowthareasinhumanhealthcareandiscommittedtoattaining leadershippositionsinthesegrowthareasthroughthedevelopmentofhighqualityinnovativeproductsandservicesnew productsintroducedwithinthepastfiveyearsaccountedforapproximatelyofsalesinbillionor ofsaleswasinvestedinresearchanddevelopmentthisinvestmentreflectsmanagementscommitmenttothe importanceofongoingdevelopmentofnewanddifferentiatedproductsandservicestosustainlongtermgrowth withmorethanoperatingcompanieslocatedincountriesthecompanyviewsitsprincipleofdecentralized managementasanassetandfundamentaltothesuccessofabroadlybasedbusinessitalsofostersanentrepreneurial spiritcombiningtheextensiveresourcesofalargeorganizationwiththeabilitytoanticipateandreactquicklytolocal marketchangesandchallenges johnsonjohnsonannualreportthecompanyiscommittedtodevelopingglobalbusinessleaderswhocanachievegrowthobjectivesbusinessesare managedforthelongterminordertosustainleadershippositionsandachievegrowththatprovidesanenduringsourceof valuetoourshareholders ourcredounifiesthemanagementteamandthecompanysdedicatedemployeesinachievingtheseobjectivesand providesacommonsetofvaluesthatserveasaconstantreminderofthecompanysresponsibilitiestoitscustomers employeescommunitiesandshareholdersthecompanybelievesthatthesebasicprinciplesalongwithitsoverall missionofimprovingthequalityoflifeforpeopleeverywherewillenablejohnsonjohnsontocontinuetobeamongthe leadersinthehealthcareindustry results operations analysisofconsolidatedsales inworldwidesalesincreasedtobillioncomparedtoanincreaseofinandadecreaseof inthesesaleschangesconsistedofthefollowing salesincreasedecreasedueto volume price currency total salesbyuscompanieswerebillioninbillioninandbillioninthisrepresentsan increaseofinanddecreasesofinandinsalesbyinternationalcompanieswere billioninbillioninandbillioninthisrepresentsincreasesofin inandintheacquisitionofsynthesincnetoftherelateddivestitureincreasedbothtotalworldwide salesgrowthandoperationalgrowthby thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively salesineuropeexperiencedadeclineofascomparedtotheprioryearincludingoperationalgrowthofoffset byanegativecurrencyimpactofsalesinthewesternhemisphereexcludingtheusachievedgrowthof ascomparedtotheprioryearincludingoperationalgrowthofandanegativecurrencyimpactofsalesinthe asiapacificafricaregionachievedgrowthofascomparedtotheprioryearincludingoperationalgrowthof andanegativecurrencyimpactof inandthecompanydidnothaveacustomerthatrepresentedormoreoftotalconsolidated revenues ushealthcarereform undertheprovisionsofthepatientprotectionandaffordablecareactandthehealthcareandeducationreconciliation actofbeginningincompaniesthatsoldbrandedprescriptiondrugstospecifiedusgovernmentprograms payanannualnontaxdeductiblefeebasedonanallocationofeachcompanysmarketshareoftotalbrandedprescription drugsalesfromtheprioryearthefullyearimpacttosellingmarketingandadministrativeexpenseswasapproximately millioninandmillioninunderthecurrentlawbeginninginthecompanywillberequired topayataxdeductibleexcisetaximposedonthesaleofcertainmedicaldevicestheexcisetaxisestimated tobebetweenmillionandwillberecordedincostofproductssoldwithinthestatementofearnings thenettradesalesimpactofthehealthcarereformlegislationwasanannualreductionofapproximatelymillionand millioninandrespectivelyduetoanincreaseinsalesrebatesanddiscounts johnsonjohnsonannualreport analysis sales business segments consumersegment consumersegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthoffsetbyanegativecurrencyimpactofusconsumersegmentsaleswerebillionadecreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbya negativecurrencyimpactof majorconsumerfranchisesales change dollarsinmillions vs vs otcpharmaceuticalsnutritionals skincare babycare womenshealth oralcare woundcareother totalconsumersales theoverthecounterotcpharmaceuticalsandnutritionalsfranchisesaleswerebillionadecreaseoffrom salesintheusdecreasedprimarilyduetolowersalesofanalgesicsasaresultofsupplyconstraintsand competitivepressuresinnutritionalproductsstronggrowthofupperrespiratorydigestivehealthandanalgesicsproducts outsidetheuswasoffsetbynegativecurrency mcneilppcinccontinuestooperateunderaconsentdecreesignedinwiththeusfoodanddrug administrationfdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationsmcneilcontinuesto operatethemanufacturingfacilitiesinlaspiedraspuertoricoandlancasterpennsylvaniahoweverproductionvolumes fromthesefacilitiescontinuetobeimpactedbyadditionalreviewandapprovalprocessesrequiredundertheconsent decreethecompanyexpectsthistocontinuethroughoutmostofplantsoperatingundertheconsentdecreewill produceasimplifiedportfoliofocusedonkeybrandsthefortwashingtonpennsylvaniamanufacturingsiteisnotin operationatthistimemcneilcontinuestoworkontheresitingoftheproductspreviouslyproducedatthefort washingtonfacilitytootherfacilities theskincarefranchisesaleswerebillioninadecreaseoffromincreasedsalesof neutrogenaproductsintheuswereoffsetbycompetitionandeconomicconditionsoutsidetheusthebaby carefranchisesaleswerebillionadecreaseoffromthedeclineinussalesandtheimpactof negativecurrencywaspartiallyoffsetbyincreasedsalesofhaircareandwipesoutsidetheusthewomenshealth franchisesaleswerebillionadecreaseofprimarilyduetotheimpactofthedivestitureofcertainbrandsthe oralcarefranchisesaleswereflatascomparedtotheprioryearincreasedsalesoflisterineproductsoutsidethe uswerepartiallyoffsetbycompetitivepressuresintheusthewoundcareotherfranchisesaleswerebillionin adecreaseoffromduetodivestituresandcompetitivepressuresnegativecurrencyimpactedallofthe franchises consumersegmentsalesinwerebillionanincreaseoffromaoperationaldeclinewas offsetbyapositivecurrencyimpactofusconsumersegmentsaleswerebillionadecreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthandapositivecurrency impactof johnsonjohnsonannualreportpharmaceutical segment thepharmaceuticalsegmentachievedsalesofbillioninrepresentinganincreaseofovertheprioryear withoperationalgrowthofandanegativecurrencyimpactofussaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthanda negativecurrencyimpactof majorpharmaceutical therapeuticareasales change dollarsinmillions vs vs totalimmunology remicade simponi stelara otherimmunology totalinfectiousdiseases intelence levaquinfloxin prezista otherinfectiousdiseases totalneuroscience concertamethylphenidate invega invegasustennaxeplion risperdalconsta otherneuroscience totaloncology doxilcaelyx velcade zytiga otheroncology totalother aciphexpariet procriteprex totalpharmaceuticalsales prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthan immunologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yeartheincreasedsalesofsimponigolimumabandremicadeinfliximabwereprimarilyduetomarketgrowth andtheimpactoftheagreementwithmerckcoincmerckeffectivejulydistributionrightstoremicade andsimponiincertainterritorieswererelinquishedtothecompanybymerckadditionalcontributorstotheincrease weresalesofstelaraustekinumab infectiousdiseaseproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtothe prioryearmajorcontributorswereincivotelaprevirthecontinuedmomentuminmarketsharegrowthofprezista darunaviredurantrilpivirineandintelenceetravirinepartiallyoffsetbylowersalesoflevaquin levofloxacinfloxinofloxacinduetothelossofmarketexclusivityintheusinjune johnsonjohnsonannualreport neuroscienceproductssaleswerebillionadeclineofascomparedtotheprioryeargrowthwasimpactedby genericcompetitionforconcertamethylphenidaterazadynegalantaminerisperdalrisperidoneand duragesicfentanyltransdermalfentanyltransdermalsystemadeclineinthecompanyslongactinginjectable antipsychoticrisperdalconstarisperidonewasoffsetbystrongsalesofinvegasustennaxeplion paliperidonepalmitateandinvegapaliperidonepalmitatethecompanysussupplyanddistributionagreement withwatsonlaboratoriesinctodistributeanauthorizedgenericversionofconcertabecameeffectivemay theoriginalconcertapatentexpiredinandthepartieshavereceivedapprovalfromthefdatomanufacture andmarketagenericversionofconcertaanothergenericversionofconcertawaslaunchedondecember thiswillresultinafurtherreductioninconcertasales oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearthisgrowthwasprimarilyduetosalesofzytigaabirateroneacetateandvelcadebortezomibthisgrowth waspartiallyoffsetbylowersalesofdoxildoxorubicinhciliposomeinjectioncaelyxpegylatedliposomal doxorubicinhydrochlorideduetosupplyconstraintsfromthecompanysthirdpartymanufacturerthecompanyhas beenworkingtorestoreareliablesupplyofdoxilcaelyxfullaccessintheushasbeenrestoredanalternate manufacturingapproachwasapprovedintheeuropeanunioneuandjapanlateinandincanadainjanuaryof intheeuropeanunionthecaelyxmanagedaccessprogramwasputinplacetoensurepatientscancomplete theirfullcourseoftreatmentitwillremaininplaceuntilafullsupplyofcaelyxhasbeenrestoredinfebruarythe fdaapprovedagenericversionofdoxil otherpharmaceuticalsaleswerebillionadeclineofascomparedtotheprioryearprimarilyduetodivestitures andlowersalesofaciphexparietrabeprazolesodiumandeprexepoetinalfaprimarilyduetotheimpactof genericcompetitiontheseresultswerepartiallyoffsetbysalesgrowthofxareltorivaroxaban duringthecompanyreceivedseveralregulatoryapprovalsincludingusapprovalofanewmgtabletof prezistadarunavirforoncedailyoraladministrationforthetreatmentofhumanimmunodeficiencyvirushivin treatmentnaiveandtreatmentexperiencedadultpatientswithnodarunavirresistanceassociatedmutationsfda approvalfortheexpandeduseofxareltorivaroxabantotreatdeepveinthrombosisordvtandpulmonary embolismorpeandtoreducetheriskofrecurrentdvtandpefollowinginitialtreatmentandthefdagranted acceleratedapprovalforsirturobedaquilinetabletsforthetreatmentofpulmonarymultidrugresistanttuberculosis aspartofcombinationtherapyinadultsthefdaapprovedthesupplementalnewdrugapplicationndafor nucyntaertapentadolextendedreleasetabletsanoralanalgesictakentwicedailyforthemanagementof neuropathicpainassociatedwithdiabeticperipheralneuropathyinadultsthefdaandtheeuropeancommissionalso approvedanexpandedindicationforzytigaabirateroneacetateincombinationwithprednisoneallowingfortheuse beforechemotherapyinthetreatmentofmetastaticcastrationresistantprostatecancerinadditiontheeuropean commissionapprovedthemarketingauthorizationsfordacogendecitabineforthetreatmentofadultpatientsage yearsandabovewithnewlydiagnoseddenovoorsecondaryacutemyeloidleukemiawhoarenotcandidatesfor standardinductionchemotherapyandforthesubcutaneousadministrationofvelcadebortezomibforthetreatment ofmultiplemyeloma thecompanysubmittedseveralnewdrugapplicationsincludinganndatothefdaandmarketingauthorization applicationmaatotheeuropeanmedicinesagencyemaseekingapprovalfortheuseofcanagliflozinanoralonce dailyselectivesodiumglucosecotransportersgltinhibitorforthetreatmentofadultpatientswithtypediabetes andanndaseekingapprovalforafixeddosetherapycombiningcanagliflozinandimmediatereleasemetformintotreat patientswithtypediabetesadditionalsubmissionsincludedasupplementalbiologicslicenseapplicationtothefda andatypeiivariationtotheemarequestingapprovalofstelaraustekinumabforthetreatmentofadultpatients withactivepsoriaticarthritisandabiologicslicenseapplicationtothefdarequestingapprovalofaninvestigational intravenousformulationoftheantitumornecrosisfactortnfalphasimponigolimumabforthetreatmentofadults withmoderatelytoseverelyactiverheumatoidarthritisinadditionasupplementalbiologicslicenseapplicationwas submittedtothefdaandatypeiivariationwassubmittedtotheemarequestingapprovalofsimponigolimumabfor thetreatmentofmoderatelytoseverelyactiveulcerativecolitisinadultpatientswhohavehadaninadequateresponseto conventionaltherapyincludingcorticosteroidsandmercaptopurinemporazathioprineazaorwhoareintolerant toorhavemedicalcontraindicationsforsuchtherapiesfinallyanmaawassubmittedtotheemaseekingconditional approvalfortheuseofbedaquilinetmcasanoraltreatmenttobeusedaspartofcombinationtherapyfor pulmonarymultidrugresistanttuberculosisinadults pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwithoperationalgrowthof andapositivecurrencyimpactofussaleswerebillionadecreaseofinternationalsaleswere billionanincreaseofwhichincludedoperationalgrowthandapositivecurrencyimpactof johnsonjohnsonannualreportmedicaldevicesanddiagnosticssegment themedicaldevicesanddiagnosticssegmentachievedsalesofbillioninrepresentinganincreaseof overtheprioryearwithoperationalgrowthofandanegativecurrencyimpactofussaleswerebillion anincreaseofascomparedtotheprioryearinternationalsaleswerebillionanincreaseofoverthe prioryearwithoperationalgrowthofandanegativecurrencyimpactoftheacquisitionofsynthesincnetof therelateddivestitureincreasedbothtotalsalesgrowthandoperationalgrowthforthemedicaldevicesanddiagnostics segmentby majormedicaldevicesanddiagnosticsfranchisesales change dollarsinmillions vs vs orthopaedics surgicalcare visioncare diabetescare specialtysurgery diagnostics cardiovascularcare infectionpreventionother totalmedicaldevicesanddiagnosticssales prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation theorthopaedicsfranchiseachievedsalesofbillioninaincreaseovertheprioryeargrowthwas primarilyduetosalesofnewlyacquiredproductsfromsynthesincandsalesofjointreconstructionandmiteksports medicineproductssaleswereimpactedbythedivestituresofthesurgicalinstrumentsbusinessofcodmanshurtleff incinthefiscalfourthquarterofandthedivestitureofcertainrightsandassetsrelatedtothedepuytrauma businessthepositiveimpactontheorthopaedicsfranchisetotalsalesgrowthandoperationalgrowthduetothenewly acquiredproductsfromsynthesincnetoftherelatedtraumabusinessdivestiturewas thesurgicalcarefranchisesaleswerebillioninadecreaseoffromtheprioryearlowersalesof mechanicalbreastcareandpelvicfloorproductswerepartiallyoffsetbyincreasedsalesofsuturesandendoscopy productswiththesuccessoftheechelonflexpoweredendopathstapler thevisioncarefranchiseachievedsalesofbillioninaincreaseovertheprioryearthegrowthwas drivenbyacuvuetrueyedayacuvuemoistforastigmatismanddayacuvuemoist thediabetescarefranchisesaleswerebillionadecreaseofversustheprioryearsalesgrowthinasiaand latinamericawasoffsetbythenegativeimpactofcurrency thespecialtysurgeryfranchiseachievedsalesofbillioninaincreaseovertheprioryearincremental salesfromtheacquisitionofsterilmedincsalesofbiosurgeryproductsandinternationalsalesofenergyproductswere themajorcontributorstothegrowth thediagnosticsfranchisesaleswerebillionadeclineofversustheprioryearthedeclinewasprimarilydueto lowersalesindonorscreeningduetocompetitivepressuresandthedivestitureoftherhogambusinessduringthe thirdquarterofinjanuarythecompanyannounceditisexploringstrategicalternativesfortheorthoclinical diagnosticsbusinessincludingapossibledivestiture thecardiovascularcarefranchisesaleswerebillionadeclineofversustheprioryearsaleswereimpacted bythecompanysdecisiontoexitthedrugelutingstentmarketinthesecondquarterofandlowersalesof endovascularproductsimpactedbycompetitivelaunchesandadisruptioninsupplythatwasresolvedlateinthethird quarterthedeclineinsaleswaspartiallyoffsetbystronggrowthinbiosensewebsterselectrophysiologybusiness primarilyduetothesuccessofthethermocoolcatheterlaunches theinfectionpreventionotherfranchiseachievedsalesofbillioninaincreaseovertheprioryear primarilyduetogrowthintheadvancedsterilizationbusiness johnsonjohnsonannualreport themedicaldevicesanddiagnosticssegmentachievedsalesofbillioninrepresentinganincreaseof overtheprioryearwithoperationalgrowthofandapositivecurrencyimpactofussaleswerebillion adecreaseofascomparedtotheprioryearinternationalsaleswerebillionanincreaseofoverthe prioryearwithoperationalgrowthofandapositivecurrencyimpactof analysis consolidated earnings provision taxes income consolidatedearningsbeforeprovisionfortaxesonincomeincreasedbybilliontobillioninas comparedtobillioninanincreaseofearningsbeforeprovisionfortaxesonincomewerefavorable duetoincreasedgrossprofitofbillionabilliondecreaseinsellingmarketingandadministrativeexpensesdue tocostcontainmentinitiativesacrossmanyofthebusinesseslowerlitigationexpenseofbillionandlowerchargesof billionrelatedtothedepuyasrhipprogramversustheprioryearthiswaspartiallyoffsetbybillionof chargesattributabletoassetwritedownsandimpairmentofinprocessresearchanddevelopmentprimarilyrelatedtothe crucellvaccinebusinessandthediscontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivandbillion ofintegrationandcurrencycostsrelatedtotheacquisitionofsynthesincversustheprioryearincludedinwasa billionrestructuringchargenetofinventorywriteoffswhichareincludedincostofproductssoldrelatedtothe cardiovascularcarebusinessadditionallyincludedhighergainsfromdivestituresandotheritemsofbillion recordedinotherincomeexpensenet thedecreaseofascomparedtowasprimarilyduetocostsassociatedwithlitigationwhichincludes productliabilitytheimpactoftheotcanddepuyasrhiprecallsandtherestructuringexpenserelatedtothe cardiovascularcarebusinessadditionallyinvestmentspendingthefeeonbrandedpharmaceuticalproductsincurred duetotheushealthcarereformlegislationandtheintegrationcostsincludinganinventorystepupchargeassociated withtheacquisitionofcrucellcontributedtothedecreaseinearningsthiswaspartiallyoffsetbygainsfromdivestitures asapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomeinwasversusin costofproductssoldandsellingmarketingandadministrativeexpensescostofproductssoldandselling marketingandadministrativeexpensesasapercenttosaleswereasfollows ofsales costofproductssold percentpointincreaseovertheprioryear sellingmarketingandadministrativeexpenses percentpointdecreaseincreaseovertheprioryear incostofproductssoldasapercenttosalesincreasedcomparedtotheprioryearthiswasprimarilytheresultof theamortizationoftheinventorystepupchargeofbillionandamortizationofintangiblesrelatedtothesynthesinc acquisitionofbillionandongoingremediationcostsinthemcneilotcbusinesstherewasadecreaseinthe percenttosalesofsellingmarketingandadministrativeexpensesincomparedtotheprioryearprimarilyduetocost containmentinitiativesacrossmanyofthebusinessestheprioryearperiodincludedhigherinvestmentspendinginthe pharmaceuticalbusinessfornewproducts incostofproductssoldasapercenttosalesincreasedcomparedtotheprioryearthiswasprimarilyattributable toongoingremediationcostsinthemcneilotcbusinessandinventorywriteoffsduetotherestructuringofthe cardiovascularcarebusinessinadditionlowermarginsandintegrationcostsincludinganinventorystepupcharge associatedwiththeacquisitionofcrucellnegativelyimpactedcostofproductssoldpercenttosalesofsellingmarketing andadministrativeexpensesincreasedincomparedtotheprioryearprimarilyduetoinvestmentspendingaswellas thefeeonbrandedpharmaceuticalproductsincurredduetotheushealthcarereformlegislation johnsonjohnsonannualreportresearchanddevelopmentexpenseresearchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillions amount ofsales amount ofsales amount ofsales consumer pharmaceutical medicaldevicesanddiagnostics totalresearchanddevelopmentexpense percentincreasedecreaseovertheprior year asapercenttosegmentsales researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsimprovingexistingproductsaswellasensuring productefficacyandregulatorycompliancepriortolaunchthecompanyremainscommittedtoinvestinginresearchand developmentwiththeaimofdeliveringhighqualityandinnovativeproductsinworldwidecostsofresearchand developmentactivitiesincreasedbycomparedtothedecreaseinthemedicaldevicesanddiagnostics segmentwasprimarilyduetothediscontinuationoftheclinicaldevelopmentprogramforthenevosirolimuseluting coronarystent inprocessresearchanddevelopmentiprdinthecompanyrecordedachargeofbillionwhich includedbillionfortheimpairmentoftheiprdrelatedtothediscontinuationofthephaseiiiclinicaldevelopmentof bapineuzumabivandthepartialimpairmentoftheiprdrelatedtothecrucellvaccinebusinessintheamountof billionofthebillionimpairmentoftheiprdrelatedtothediscontinuationofthephaseiiiclinicaldevelopmentof bapineuzumabivbillionisattributabletononcontrollinginterestthesechargesrelatetodevelopmentprojects whichhavebeenrecentlydiscontinuedordelayed otherincomeexpensenetotherincomeexpensenetincludesroyaltyincomegainsandlossesrelatedtothe saleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnsondevelopmentcorporation gainsandlossesonthedisposalofpropertyplantandequipmentcurrencygainsandlossesandlitigationsettlementsin thefavorablechangeofbillioninotherincomeexpensenetwasprimarilyduetolowerexpensesof billionrelatedtolitigationincludingproductliabilityandbillionforcostsrelatedtothedepuyasrhipprogram thiswaspartiallyoffsetbybillionattributedtoassetwritedownsprimarilyrelatedtothecrucellvaccinebusiness andbillionofhigherintegrationtransactionandcurrencycostsrelatedtotheacquisitionofsynthesinc intheunfavorablechangeofbillioninotherincomeexpensenetwasprimarilyduetonetlitigationwhich includesproductliabilityofbillioninascomparedtoabillionnetgainfromlitigationinadditionally ascomparedtoincludedhigherexpensesofbillionforcostsrelatedtothedepuyasrhipprogram andanadjustmentofbilliontothevalueofthecurrencyoptionanddealcostsrelatedtotheacquisitionofsynthes incincludedinwerehighergainsonthedivestituresofbusinessesofbillionascomparedto restructuringincordiscorporationasubsidiaryofjohnsonjohnsonannouncedthediscontinuationofits clinicaldevelopmentprogramforthenevosirolimuselutingcoronarystentandcessationofthemanufactureand marketingofcypherandcypherselectplussirolimuselutingcoronarystentsbytheendofthe companyrecordedapretaxchargeofbillionofwhichbillionwasincludedinthecostofproductssoldthere wasnorestructuringchargeinseenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelated totherestructuring interestincomeexpenseinterestincomeindecreasedbymillionascomparedtotheprioryeardueto lowerratesofinterestearnedandloweraveragecashbalancescashcashequivalentsandmarketablesecuritiestotaled billionattheendofandaveragedbillionascomparedtothebillionaveragecashbalancein thedeclineintheaveragecashbalancewasduetotheacquisitionofsynthesincpartiallyoffsetbycash generatedfromoperatingactivities interestexpenseindecreasedbymillionascomparedtoduetoaloweraveragedebtbalancethe averagedebtbalancewasbillioninversusbillioninthetotaldebtbalanceattheendof wasbillionascomparedtobillionattheendofthereductionindebtofapproximatelybillionwas primarilyduetoareductionincommercialpaper johnsonjohnsonannualreport interestincomeindecreasedbymillionascomparedtotheprioryearduetolowerratesofinterestearned despitehigheraveragecashbalancescashcashequivalentsandmarketablesecuritiestotaledbillionattheendof andaveragedbillionascomparedtothebillionaveragecashbalanceintheincreaseinthe averagecashbalancewasprimarilyduetocashgeneratedfromoperatingactivitiesandnetcashproceedsfrom divestitures interestexpenseinincreasedbymillionascomparedtoduetoahigheraveragedebtbalancethetotal debtbalanceattheendofwasbillionascomparedtobillionattheendofthehigheraverage debtbalanceofbillioninversusbillioninwasduetoincreasedborrowingsthecompany increasedborrowingscapitalizingonfavorabletermsinthecapitalmarketstheproceedsoftheborrowingswereused forgeneralcorporatepurposes segmentpretaxprofit pretaxprofitsbysegmentofbusinesswereasfollows percentof segmentsales dollarsinmillions consumer pharmaceutical medicaldevicesanddiagnostics total lessexpensesnotallocatedtosegments earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetails amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincome expenseabillionandbillioncurrencyrelatedexpensefortheacquisitionofsynthesincwasincludedinand respectively consumersegmentinconsumersegmentpretaxprofitasapercenttosaleswasversusin pretaxprofitwasunfavorablyimpactedbybillionattributedtointangibleassetwritedownsandapproximately billionduetounfavorableproductmixandremediationcostsassociatedwiththemcneilppcincconsentdecree thiswaspartiallyoffsetbycostcontainmentinitiativesrealizedinsellingmarketingandadministrativeexpensesin additionincludedhighergainsondivestituresinconsumersegmentpretaxprofitdecreasedfrom theprimarydriversofthedeclineinoperatingprofitwereunfavorableproductmixandremediationcostsassociated withtherecallofcertainotcproductspartiallyoffsetbythegainonthedivestitureofmonistat pharmaceuticalsegmentinpharmaceuticalsegmentpretaxprofitasapercenttosaleswasversus inpretaxprofitwasunfavorablyimpactedbychargesofbillionattributedtothewritedownofassets andimpairmentofinprocessresearchanddevelopmentassetsrelatedtothecrucellvaccinebusinessandtothe discontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivthiswaspartiallyoffsetbylowerlitigation expenseofbillionversustheprioryearandfavorableoperatingexpensesofbillionadditionallyincluded thegainonthedivestitureofbystolicnebivololiprightsinpharmaceuticalsegmentpretaxprofitdecreased fromtheprimarydriversofthedecreaseinthepretaxprofitmarginwerehigherlitigationexpensesrecorded intheimpactoftheushealthcarereformfeeandlowermarginsandintegrationcostsincludinganinventory stepupchargeassociatedwiththecrucellacquisitionthiswaspartiallyoffsetbygainsonthedivestituresoftheanimal healthbusinessandorthodermatologicsthegainrelatedtothecompanysearlierinvestmentincrucellandlower manufacturingcosts medicaldevicesanddiagnosticssegmentinmedicaldevicesanddiagnosticssegmentpretaxprofitasa percenttosaleswasversusinthemedicaldevicesanddiagnosticssegmentpretaxprofitwas favorablyimpactedbyprofitsfromsynthessaleslowerexpensesofbillionforlitigationincludingproductliability andthedepuyasrhipprogramandbillionforresearchanddevelopmentprimarilyduetothediscontinuationof itsclinicaldevelopmentprogramforthenevosirolimuselutingcoronarystentthiswaspartiallyoffsetbyanincrease inintegrationcostsandamortizationoftheinventorystepupofbillionassociatedwiththeacquisitionofsynthes incandbillionattributedtothewritedownofintangibleassetsinadditionincludedhighergainson johnsonjohnsonannualreportdivestituresversustheprioryearduetothedivestituresofthetherakosbusinessandrhogamadditionally includedabillionrestructuringchargerelatedtothediscontinuationoftheclinicaldevelopmentprogramforthe nevosirolimuselutingcoronarystentinmedicaldevicesanddiagnosticssegmentpretaxprofitdecreased fromtheprimarydriversofthedeclineinthepretaxprofitmargininthemedicaldevicesanddiagnostics segmentwerelitigationexpensesincludingproductliabilitycostsassociatedwiththedepuyasrhipprogram restructuringexpensecostsincurredrelatedtotheacquisitionofsynthesincandincreasedinvestmentspending provisionfortaxesonincometheworldwideeffectiveincometaxratewasininand intheincreaseintheeffectivetaxrateofascomparedtowasduetolowertaxbenefits ontheimpairmentofinprocessresearchanddevelopmentintangibleassetsinlowtaxjurisdictionsincreasesintaxable incomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsandtheexclusionofthebenefitoftheusresearch developmentrdtaxcreditandthecfclookthroughprovisionsfromthefiscalyearfinancialresultstherd taxcreditandthecfclookthroughprovisionswereenactedintolawinandwereretroactivetojanuary theentirebenefitoftherdtaxcreditandthecfclookthroughprovisionswillbereflectedinthefiscalyear financialresults thetaxrateincreasedascomparedtoduetocertainusexpenseswhicharenotfullytaxdeductibleand higherusstatetaxespartiallyoffsetbyincreasesintaxableincomeinlowertaxjurisdictionsrelativetohighertax jurisdictions noncontrollinginterestachargeofbillionfortheimpairmentoftheiprdrelatedtothediscontinuationofthe phaseiiiclinicaldevelopmentofbapineuzumabivwasrecordedinofthebillionimpairmentbillionis attributabletononcontrollinginterest liquidity capital resources liquiditycashflows cashandcashequivalentswerebillionattheendofascomparedwithbillionattheendofthe primaryusesofcashthatcontributedtothebilliondecreaseversustheprioryearwereapproximatelybillionnet cashusedbyinvestingactivitiesandbillionnetcashusedbyfinancingactivitiespartiallyoffsetbybillionof cashgeneratedfromoperatingactivities cashflowfromoperationsofbillionwastheresultofbillionofnetearningsandbillionofnoncash chargesprimarilyrelatedtodepreciationandamortizationassetwritedownsprimarilyinprocessresearchand developmentstockbasedcompensationnoncontrollinginterestanddeferredtaxprovisionreducedbybillion relatedtochangesinassetsandliabilitiesnetofeffectsfromacquisitions investingactivitiesuseofbillionwasprimarilyforbillionforadditionstopropertyplantandequipmentand acquisitionsnetofcashacquiredofbillionpartiallyoffsetbynetsalesofinvestmentsinmarketablesecuritiesof billionandbillionofproceedsfromthedisposalofassets financingactivitiesuseofbillionwasfortherepurchaseofcommonstockofbillionprimarilyforthe acquisitionofsynthesincdividendstoshareholdersofbillionandnetretirementofshortandlongtermdebtof billionpartiallyoffsetbybillionofnetproceedsfromstockoptionsexercisedexcesstaxbenefits inthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketforadditionaldetails onborrowingsseenotetotheconsolidatedfinancialstatements thecompanyanticipatesthatoperatingcashflowsexistingcreditfacilitiesandaccesstothecommercialpapermarkets willprovidesufficientresourcestofundoperatingneedsin concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitsrecenteconomicchallengesin italyspaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccounts receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofdecemberand johnsonjohnsonannualreport approximatelybillionasofjanuaryapproximatelybillionasofdecemberandapproximately billionasofjanuaryofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothe companysconsumervisioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevices anddiagnosticscustomerswhichareinlinewithhistoricalcollectionpatterns theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacted bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldevicesanddiagnosticslocalaffiliatesthetotalnettradeaccounts receivablebalanceforthesecustomerswereapproximatelybillionatdecemberandbillionat januarythecompanycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepayment premiumsforcustomerswherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtrade receivableshavebeendiscountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshave beenincreasedforthesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywith thesecustomersonpaymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosses onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthedecembermarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthedecembermarketrateswoulddecrease theunrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflows thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflows thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastanaorequivalentcreditratingthecounterparties tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremote thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfees undertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelythereductionindebtin ofapproximatelybillionwasprimarilyduetoareductionincommercialpaper innetcashcashandcurrentmarketablesecuritiesnetofdebtwasbillioncomparedtonetcashof billionintotaldebtrepresentedoftotalcapitalshareholdersequityandtotaldebtinand oftotalcapitalinshareholdersequitypershareattheendofwascomparedtoat yearendanincreaseof asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatements johnsonjohnsonannualreportcontractualobligationsandcommitments thecompanyscontractualobligationsareprimarilyforleasesdebtandunfundedretirementplanstherearenoother significantobligationstosatisfytheseobligationsthecompanywillusecashfromoperationsthefollowingtable summarizesthecompanyscontractualobligationsandtheiraggregatematuritiesasofdecemberseenotes andtotheconsolidatedfinancialstatementsforfurtherdetails longterm intereston unfunded debt debt retirement operating dollarsinmillions obligations obligations plans leases total total fortaxmattersseenotetotheconsolidatedfinancialstatements sharerepurchase anddividends onjulythecompanyannouncedthatitsboardofdirectorsapprovedastockrepurchaseprogramauthorizing thecompanytobuybackuptobillionofthecompanyscommonstockasofjanuarythecompany repurchasedanaggregateofmillionsharesofjohnsonjohnsoncommonstockatacostofbillionandthe stockrepurchaseprogramwascompletedthecompanyfundedthesharerepurchaseprogramthroughacombinationof availablecashanddebt pursuanttotheacceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofsynthesincthe companyhasnotmadeanypurchasesofcommonstockontheopenmarketduringthefiscalthirdandfourthquartersof thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein comparedwithdividendsofpershareinandpershareinthedividendsweredistributed asfollows firstquarter secondquarter thirdquarter fourthquarter total onjanuarytheboardofdirectorsdeclaredaregularquarterlycashdividendofpersharepayableon marchtoshareholdersofrecordasoffebruarythecompanyexpectstocontinuethepracticeof payingregularcashdividends johnsonjohnsonannualreport information criticalaccountingpoliciesandestimates managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompanys consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosures actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockoptions revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordeliveredand titleandriskoflosspasstothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscoupons productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsales arerecorded productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebatesthelargestbeingthemedicaidrebate provisionareestimatedbasedoncontractualtermshistoricalexperiencetrendanalysisandprojectedmarketconditions inthevariousmarketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarily throughtheanalysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternally generatedinformation salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedand analyzedaspartoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicesanddiagnosticssegmentaretypicallyresalablebutarenotmaterialthe companyrarelyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompany hasrangedbetweenandofannualnettradesalesduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebased incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold thecompanyalsoearnsservicerevenueforcopromotionofcertainproductsforallyearspresentedservicerevenues werelessthanoftotalrevenuesandareincludedinsalestocustomersthesearrangementsareevaluatedto determinetheappropriateamountstobedeferred inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered basedontherelativefairvalueupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedoverthe performanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaborations reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchanges toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact johnsonjohnsonannualreportbelowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendeddecemberandjanuary consumersegment balanceat balanceat beginningof payments endof dollarsinmillions period accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatjanuaryrecordedasacontra asset pharmaceutical segment balanceat balanceat beginningof payments endof dollarsinmillions period accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatjanuaryrecordedasa contraasset johnsonjohnsonannualreport medicaldevicesanddiagnosticssegment balanceat balanceat beginningof payments endof dollarsinmillions period accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatjanuaryrecordedasa contraasset incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilities thecompanyestimatesdeferredtaxassetsandliabilitiesbasedoncurrenttaxregulationsandrateschangesintaxlaws andratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atdecemberandjanuarythecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatdecemberandjanuarythecompanys foreignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsofbillionandbillion respectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational subsidiarieswheretheearningsareconsideredtobepermanentlyreinvestedthecompanyintendstocontinueto reinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatetheseearningsto theusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompanydoesnot determinethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnotpractical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyandisinsureduptocertainlimitsin additiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesare probableandamountscanbereasonablyestimatedadditionallythecompanyrecordsinsurancereceivableamounts fromthirdpartyinsurerswhenrecoveryisprobableasappropriatereservesagainstthesereceivablesarerecordedfor estimatedamountsthatmaynotbecollectedfromthirdpartyinsurers thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued johnsonjohnsonannualreportlonglivedandintangibleassetsthecompanyassesseschangesineconomicconditionsandmakesassumptions regardingestimatedfuturecashflowsinevaluatingthevalueofthecompanyspropertyplantandequipmentgoodwill andintangibleassetsastheseassumptionsandestimatesmaychangeovertimeitmayormaynotbenecessaryforthe companytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsexpectedsalaryincreasesandhealthcarecosttrend ratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsontheseratesandtheeffectaratechange wouldhaveonthecompanysresultsofoperations stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesthefairvalueofeachawardisestimatedonthedateofgrantusingtheblack scholesoptionvaluationmodelandisexpensedinthefinancialstatementsoverthevestingperiodtheinputassumptions usedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandthedividendyieldseenoteto theconsolidatedfinancialstatementsforadditionalinformation newaccountingpronouncements refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofdecember economicandmarketfactors thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymakers consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcerns thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheunited statestheweightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproducts prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi inflationratescontinuetohaveaneffectonworldwideeconomiesandconsequentlyonthewaycompaniesoperatethe companyaccountedforoperationsinvenezuelaashighlyinflationaryinandasthepriorthreeyear cumulativeinflationratesurpassedinthefaceofincreasingcoststhecompanystrivestomaintainitsprofit marginsthroughcostreductionprogramsproductivityimprovementsandperiodicpriceincreases onfebruarythevenezuelangovernmentannouncedadevaluationofitscurrencytheeffectofthe devaluationisnotexpectedtohaveamaterialimpactonthecompanysfullyearresults thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandincomebymillion thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare products changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaying medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompanys businesses thecompanyalsooperatesinanenvironmentwhichhasbecomeincreasinglyhostiletointellectualpropertyrights genericdrugfirmshavefiledabbreviatednewdrugapplicationsandasseekingtomarketgenericformsofmostofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedinandafilingsthegenericfirmswillthen introducegenericversionsoftheproductatissueresultinginthepotentialforsubstantialmarketshareandrevenue lossesforthatproductforfurtherinformationseethediscussiononlitigationagainstfilersofabbreviatednewdrug applicationsinnotetotheconsolidatedfinancialstatements johnsonjohnsonannualreport legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount ofthelosscanbereasonablyestimatedthecompanyhasaccruedforcertainlitigationmattersandcontinuestomonitor eachrelatedlegalissueandadjustaccrualsfornewinformationandfurtherdevelopmentsinaccordancewithaccounting standardscodificationascfortheseandotherlitigationandregulatorymatterscurrentlydisclosedfor whichalossisprobableorreasonablypossiblethecompanyisunabletodetermineanestimateofthepossiblelossor rangeoflossbeyondtheamountsalreadyaccruedthesematterscanbeaffectedbyvariousfactorsincludingwhether damagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnot commencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificant factsindisputeortherearenumerouspartiesinvolved inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutioninanyreportingperiodofone ormoreofthesematterseitheraloneorintheaggregatemayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceedings commonstockmarketprices thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompanythecompositemarketpricerangesfor johnsonjohnsoncommonstockduringandwere high low high low firstquarter secondquarter thirdquarter fourthquarter yearendclose johnsonjohnsonannualreportcautionary factors may affect future results thisannualreportcontainsforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalor currentfactsandanticipateresultsbasedonmanagementsplansthataresubjecttouncertaintyforwardlooking statementsmaybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandother wordsofsimilarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsfinancialperformance thecompanysstrategyforgrowthproductdevelopmentregulatoryapprovalmarketpositionandexpenditures forwardlookingstatementsarebasedoncurrentexpectationsoffutureeventsthecompanycannotguaranteethatany forwardlookingstatementwillbeaccuratealthoughthecompanybelievesthatithasbeenreasonableinitsexpectations andassumptionsinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorthatunknownrisksor uncertaintiesmaterializeactualresultscouldvarymateriallyfromthecompanysexpectationsandprojectionsinvestors arethereforecautionednottoplaceunduerelianceonanyforwardlookingstatementsthecompanydoesnotundertake toupdateanyforwardlookingstatementsasaresultofnewinformationorfutureeventsordevelopments risksanduncertaintiesincludebutarenotlimitedtogeneralindustryconditionsandcompetitioneconomicfactorssuch asinterestrateandcurrencyexchangeratefluctuationstechnologicaladvancesnewproductsandpatentsattainedby competitorschallengesinherentinnewproductdevelopmentincludingobtainingregulatoryapprovalschallengesto patentssignificantlitigationorgovernmentactionadversetothecompanyimpactofbusinesscombinationsfinancial distressandbankruptciesexperiencedbysignificantcustomersandsupplierschangestogovernmentallawsand regulationsandusandforeignhealthcarereformstrendstowardhealthcarecostcontainmentincreasedscrutinyof thehealthcareindustrybygovernmentagencieschangesinbehaviorandspendingpatternsofpurchasersofhealthcare productsandservicesfinancialinstabilityofinternationaleconomiesandsovereignriskdisruptionsduetonatural disastersmanufacturingdifficultiesordelayscomplexglobalsupplychainswithincreasingregulatoryrequirementsand productefficacyorsafetyconcernsresultinginproductrecallsorregulatoryaction thecompanysreportonformkfortheyearendeddecemberincludesinexhibitadiscussionof additionalfactorsthatcouldcauseactualresultstodifferfromexpectationsthecompanynotesthesefactorsas permittedbytheprivatesecuritieslitigationreformactof johnsonjohnsonannualreport johnson johnson subsidiaries consolidated balance sheets atdecemberandjanuary dollarsinmillionsexceptshareandpershareamountsnote assets currentassets cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccounts inventoriesnotesand deferredtaxesonincomenote prepaidexpensesandotherreceivables totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherassets totalassets liabilitiesandshareholdersequity currentliabilities loansandnotespayablenote accountspayable accruedliabilities accruedrebatesreturnsandpromotions accruedcompensationandemployeerelatedobligations accruedtaxesonincome totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand otherliabilities totalliabilities shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshares commonstockparvaluepersharenoteauthorizedsharesissued shares accumulatedothercomprehensiveincomenote retainedearnings lesscommonstockheldintreasuryatcostnotesharesandshares totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements earnings dollarsandsharesinmillionsexceptpershareamountsnote salestocustomers costofproductssold grossprofit sellingmarketingandadministrativeexpenses researchanddevelopmentexpense inprocessresearchanddevelopmentnote interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearnings addnetlossattributabletononcontrollinginterest netearningsattributabletojohnsonjohnson netearningspershareattributabletojohnsonjohnsonnotesand basic diluted cashdividendspershare averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements comprehensive income dollarsinmillionsnote netearnings othercomprehensiveincomelossnetoftax foreigncurrencytranslation securities unrealizedholdinggainlossarisingduringperiod reclassificationstoearnings netchange employeebenefitplans priorservicecostamortizationduringperiod priorservicecostcurrentyear gainlossamortizationduringperiod gainlosscurrentyear effectofexchangerates netchange derivativeshedges unrealizedgainlossarisingduringperiod reclassificationstoearnings netchange othercomprehensiveincomeloss comprehensiveincome comprehensivelossattributabletononcontrollinginterestnetoftax comprehensiveincomeattributabletojohnsonjohnson thetaxeffectsinothercomprehensiveincomeforthefiscalyearsendedandrespectivelysecurities millionmillionandmillionemployeebenefitplansmillionmillionandmillion derivativeshedgesmillionmillionandmillion foreigncurrencytranslationisnotadjustedforincometaxesasitrelatestopermanentinvestmentsininternational subsidiaries seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements equity dollarsinmillionsnote accumulated treasury retained comprehensive commonstock stock total earnings income issuedamount amount balancejanuary netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax balancejanuary netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax balancejanuary netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans issuanceofcommonstockassociatedwiththe acquisitionofsynthesinc repurchaseofcommonstock othercomprehensiveincomenetoftax balancedecember includesrepurchaseofcommonstockassociatedwiththeacquisitionofsynthesinc seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements cash flows dollarsinmillionsnote cashflowsfromoperatingactivities netearnings adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities depreciationandamortizationofpropertyandintangibles stockbasedcompensation noncontrollinginterest assetwritedownsandimpairments deferredtaxprovision accountsreceivableallowances changesinassetsandliabilitiesnetofeffectsfromacquisitions increaseinaccountsreceivable increaseininventories increaseinaccountspayableandaccruedliabilities increaseinothercurrentandnoncurrentassets decreaseincreaseinothercurrentandnoncurrentliabilities netcashflowsfromoperatingactivities cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassets acquisitionsnetofcashacquirednote purchasesofinvestments salesofinvestments otherprimarilyintangibles netcashusedbyinvestingactivities cashflowsfromfinancingactivities dividendstoshareholders repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebt retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsexcesstaxbenefits netcashusedbyfinancingactivities effectofexchangeratechangesoncashandcashequivalents decreaseincreaseincashandcashequivalents cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest incometaxes supplementalscheduleofnoncashinvestingandfinancingactivities issuanceofcommonstockassociatedwiththeacquisitionofsynthesinc treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceeds conversionofdebt acquisitions fairvalueofassetsacquired fairvalueofliabilitiesassumedandnoncontrollinginterests netfairvalueofacquisitions lessissuanceofcommonstockassociatedwiththeacquisitionofsynthesinc netcashpaidforacquisitions seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportnotes consolidated financial statements summaryofsignificantaccountingpolicies principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminated descriptionofthecompanyandbusinesssegments thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesand diagnosticstheconsumersegmentincludesabroadrangeofproductsusedinthebabycareskincareoralcare woundcareandwomenshealthfieldsaswellasnutritionalandoverthecounterpharmaceuticalproductsandwellness andpreventionplatformstheseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutletsand distributorsthroughouttheworldthepharmaceuticalsegmentincludesproductsinthefollowingareasantiinfective antipsychoticcontraceptivegastrointestinalhematologyimmunologyinfectiousdiseasesneurologyoncologypain managementthrombosisandvaccinestheseproductsaredistributeddirectlytoretailerswholesalersandhealthcare professionalsforprescriptionusethemedicaldevicesanddiagnosticssegmentincludesabroadrangeofproducts distributedtowholesalershospitalsandretailersusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitals andclinicstheseincludeproductstotreatcardiovasculardiseaseorthopaedicandneurologicalproductsbloodglucose monitoringandinsulindeliveryproductsgeneralsurgerybiosurgicalandenergyproductsprofessionaldiagnostic productsinfectionpreventionproductsanddisposablecontactlenses newaccountingpronouncements recentlyadoptedaccountingpronouncements duringthefiscalfirstquarterofthecompanyadoptedthefinancialaccountingstandardsboardfasbguidance andamendmentsissuedrelatedtogoodwillimpairmenttestingundertheamendmentsinthisupdateanentityhasthe optiontofirstassessqualitativefactorstodeterminewhethertheexistenceofeventsorcircumstancesleadstoa determinationthatitismorelikelythannotthatthefairvalueofareportingunitislessthanitscarryingamountifafter assessingthetotalityofeventsorcircumstancesanentitydeterminesitisnotmorelikelythannotthatthefairvalueofa reportingunitislessthanitscarryingamountthenperformingthetwostepimpairmenttestisunnecessaryhoweverifan entityconcludesotherwisethenitisrequiredtoperformthefirststepofthetwostepimpairmenttestthisupdate becameeffectiveforannualandinterimgoodwillimpairmenttestsperformedforfiscalyearsbeginningafterdecember theadoptionofthisstandarddidnothaveamaterialimpactonthecompanysresultsofoperationscashflowsor financialposition duringthefiscalfirstquarterofthecompanyadoptedthefasbamendmenttothedisclosurerequirementsfor presentationofcomprehensiveincometheamendmentrequiresthatallnonownerchangesinstockholdersequitybe presentedeitherinasinglecontinuousstatementofcomprehensiveincomeorintwoseparatebutconsecutive statementsthisguidancebecameeffectiveretrospectivelyfortheinterimperiodsandannualperiodsbeginningafter december duringthefiscalfirstquarterofthecompanyadoptedthefasbamendmentstodisclosurerequirementsforfair valuemeasurementtheseamendmentsresultinconvergenceoffairvaluemeasurementanddisclosurerequirements betweenusgenerallyacceptedaccountingprinciplesgaapandinternationalfinancialreportingstandardsifrs thisguidancebecameeffectiveprospectivelyfortheinterimperiodsandannualperiodsbeginningafterdecember theadoptionofthisstandarddidnothaveamaterialimpactonthecompanysresultsofoperationscashflowsor financialposition johnsonjohnsonannualreport recentlyissuedaccountingstandards notadoptedasofdecember duringthefiscalthirdquarterofthefasbissuedguidanceandamendmentsrelatedtotestingindefinitelived intangibleassetsforimpairmentundertheamendmentsinthisupdateanentityhastheoptiontofirstassessqualitative factorstodeterminewhethertheexistenceofeventsorcircumstancesindicatesthatitismorelikelythannotthatthe indefinitelivedintangibleassetisimpairedifafterassessingthetotalityofeventsandcircumstancesanentityconcludes thatitisnotmorelikelythannotthattheindefinitelivedintangibleassetisimpairedthentheentityisnotrequiredto determinethefairvaluehoweverifanentityconcludesotherwisethenitisrequiredtodeterminethefairvalueofthe indefinitelivedintangibleassetandperformthequantitativeimpairmenttestanentityalsohastheoptiontobypassthe qualitativeassessmentforanyindefinitelivedintangibleassetinanyperiodandproceeddirectlytoperformingthe quantitativeimpairmenttestthisupdatebecameeffectiveforannualandinterimimpairmenttestsperformedforfiscal yearsbeginningafterseptember howeverearlyadoptionispermittedtheadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthe companysresultsofoperationscashflowsorfinancialposition infebruarythefasbissuedguidancerelatedtoadditionalreportinganddisclosureofamountsreclassifiedoutof accumulatedothercomprehensiveincomeociunderthisnewguidancecompanieswillberequiredtodisclosethe amountofincomeorlossreclassifiedoutofocitoeachrespectivelineitemontheincomestatementofwherenet incomeispresentedtheguidanceallowscompaniestoelectwhethertodisclosethereclassificationeitherinthenotesto thefinancialstatementsoronthefaceoftheincomestatementthisupdateiseffectiveforannualandinterimreporting periodsforfiscalyearsbeginningafterdecembertheadoptionofthisstandardisnotexpectedhaveamaterial impactonthecompanysresultsofoperationscashflowsorfinancialposition cashequivalents thecompanyconsiderssecuritieswithmaturitiesofthreemonthsorlesswhenpurchasedtobecashequivalents investments shorttermmarketablesecuritiesarecarriedatcostwhichapproximatesfairvalueinvestmentsclassifiedasavailablefor salearecarriedatestimatedfairvaluewithunrealizedgainsandlossesrecordedasacomponentofaccumulatedother comprehensiveincomelongtermdebtsecuritiesthatthecompanyhastheabilityandintenttoholduntilmaturityare carriedatamortizedcostmanagementdeterminestheappropriateclassificationofitsinvestmentindebtandequity securitiesatthetimeofpurchaseandreevaluatessuchdeterminationateachbalancesheetdatethecompany periodicallyreviewsitsinvestmentsinequitysecuritiesforimpairmentandadjuststheseinvestmentstotheirfairvalue whenadeclineinmarketvalueisdeemedtobeotherthantemporaryiflossesonthesesecuritiesareconsideredtobe otherthantemporarythelossisrecognizedinearnings propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheassets buildingandbuildingequipment years landandleaseholdimprovements years machineryandequipment years thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflows johnsonjohnsonannualreportrevenue recognition thecompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss passtothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscouponsproductreturnsand discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorded productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebatesthelargestbeingthemedicaidrebate provisionareestimatedbasedoncontractualtermshistoricalexperiencetrendanalysisandprojectedmarketconditions inthevariousmarketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarily throughtheanalysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternally generatedinformation salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedand analyzedaspartoftheaccountingforsalesreturnsaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewithusgaap guidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsalesvaluesales returnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsforcertain franchisesinthemedicaldevicesanddiagnosticssegmentaretypicallyresalablebutarenotmaterialthecompany rarelyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhas rangedbetweenandofannualsalestocustomersduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebased incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare soldthecompanyalsoearnsservicerevenueforcopromotionofcertainproductsandincludesitinsalestocustomers thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferred shippingandhandling shippingandhandlingcostsincurredweremillionmillionandmillioninand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresented inventories inventoriesarestatedatthelowerofcostormarketdeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed annuallyforimpairmentthecompanycompletedtheannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedaswasthecaseforcertain indefinitelivedintangibleassetsinthefiscalsecondandthirdquartersofpurchasedinprocessresearchand developmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompletedatwhich pointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpointthe intangibleassetwillbewrittenofforpartiallyimpaired intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstruments asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement johnsonjohnsonannualreport determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instruments productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationtheaccrualsare adjustedperiodicallyasadditionalinformationbecomesavailable asaresultofcostandavailabilityfactorseffectivenovemberthecompanyceasedpurchasingthirdparty productliabilityinsurancethecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyandis insureduptocertainlimitsinadditiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurance coverageareaccruedwhenlossesareprobableandamountscanbereasonablyestimatedbasedontheavailabilityof priorcoveragereceivablesforinsurancerecoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscounted basiswhenitisprobablethatarecoverywillberealizedasappropriatereservesagainstthesereceivablesarerecorded forestimatedamountsthatmaynotbecollectedfromthirdpartyinsurers concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitsrecenteconomicchallengesin italyspaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccounts receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofdecemberand approximatelybillionasofjanuaryapproximatelybillionasofdecemberandapproximately billionasofjanuaryofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothe companysconsumervisioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevices anddiagnosticscustomerswhichareinlinewithhistoricalcollectionpatterns theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacted bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldevicesanddiagnosticslocalaffiliatesthetotalnettradeaccounts receivablebalanceforthesecustomerswereapproximatelybillionatdecemberandbillionat januarythecompanycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepayment premiumsforcustomerswherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtrade receivableshavebeendiscountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshave beenincreasedforthesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywith thesecustomersonpaymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredupfrontandmilestonepaymentsmadetothirdpartiesin connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful lifeoftherelatedproductamountscapitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulated amortization johnsonjohnsonannualreportthecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract developmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollows naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproduct salestocustomers royaltiesmilestonespaidtocollaborativepartner costofgoodssold postregulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartner milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidated researchanddevelopmentexpense advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninandrespectively incometaxes incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedoncurrenttaxregulationsandrateschangesintaxlawsandratesmay affectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atdecemberandjanuarythecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatdecemberandjanuarythecompanys foreignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsofbillionandbillion respectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational subsidiarieswheretheearningsareconsideredtobepermanentlyreinvestedthecompanyintendstocontinueto reinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatetheseearningsto theusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompanydoesnot determinethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnotpracticable seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes johnsonjohnsonannualreport netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimates thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxesdepreciation amortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresultsmayormaynot differfromthoseestimates thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks aswasthecaseinandwillbethecaseagainin reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation cashcashequivalentsandcurrentmarketablesecurities attheendofandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof dollarsinmillions cash governmentsecuritiesandobligations corporatedebtsecurities moneymarketfunds timedeposits totalcashcashequivalentsandcurrentmarketablesecurities theestimatedfairvaluewasthesameastheamortizedcostasofdecembertheestimatedfairvaluewas millionasofjanuaryreflectingamillionunrealizedgainingovernmentsecuritiesandobligations asofdecembercurrentmarketablesecuritiesconsistedofmillionandmillionofgovernment securitiesandobligationsandcorporatedebtsecuritiesrespectively asofjanuarycurrentmarketablesecuritiesconsistedofmillionandmillionofgovernment securitiesandobligationsandcorporatedebtsecuritiesrespectively fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinputs thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastanaorequivalentcreditrating johnsonjohnsonannualreport inventories attheendofandinventorieswerecomprisedof dollarsinmillions rawmaterialsandsupplies goodsinprocess finishedgoods totalinventories asofdecembertheremaininginventorystepuprelatedtothesynthesincacquisitionisapproximately million propertyplantandequipment attheendofandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillions landandlandimprovements buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestinandwasbillion billionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulated depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearnings intangibleassetsandgoodwill attheendofandthegrossandnetamountsofintangibleassetswere dollarsinmillions intangibleassetswithdefinitelives patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelives trademarks purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelives totalintangibleassetsnet johnsonjohnsonannualreport goodwillasofdecemberandjanuaryasallocatedbysegmentofbusinesswasasfollows meddevices dollarsinmillions consumer pharmaceuticals diagnostics total goodwillatjanuary acquisitions currencytranslationother goodwillatjanuary acquisitions currencytranslationother goodwillatdecember theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible assetsareyearsandyearsrespectivelytheamortizationexpenseofamortizableassetswasmillion millionandmillionbeforetaxforthefiscalyearsendeddecemberjanuaryandjanuary respectivelytheestimatedamortizationexpenseforthefivesucceedingyearsapproximatesmillionbefore taxperyearamortizationexpenseisincludedincostofproductssold intangibleassetsandgoodwillincreasedbybillionandbillionrespectivelybasedonthepurchaseprice allocationforthesynthesincacquisitionseenotetotheconsolidatedfinancialstatementsforadditionaldetailson thesynthesincacquisitiontheincreaseinintangibleassetswaspartiallyoffsetbybillioninintangibleassetwrite downsandabillionimpairmentofpurchasedinprocessresearchanddevelopmentprimarilyrelatedtothe discontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivandthepartialimpairmentrelatedtothecrucell vaccinebusiness fairvaluemeasurements thecompanyusesforwardexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarilyrelatedto theforeignexchangeratechangesoffutureintercompanyproductandthirdpartypurchasesofrawmaterials denominatedinforeigncurrencythecompanyalsousescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedgesthecompanyalsouses forwardexchangecontractstomanageitsexposuretothevariabilityofcashflowsforrepatriationofforeigndividends thesecontractsaredesignatedasnetinvestmenthedgesadditionallythecompanyusesforwardexchangecontractsto offsetitsexposuretocertainforeigncurrencyassetsandliabilitiestheseforwardexchangecontractsarenotdesignated ashedgesandthereforechangesinthefairvaluesofthesederivativesarerecognizedinearningstherebyoffsettingthe currentearningseffectoftherelatedforeigncurrencyassetsandliabilitiesthecompanydoesnotenterintoderivative financialinstrumentsfortradingorspeculativepurposesorcontaincreditriskrelatedcontingentfeaturesorrequirements topostcollateralonanongoingbasisthecompanymonitorscounterpartycreditratingsthecompanyconsiderscredit nonperformancerisktobelowbecausethecompanyentersintoagreementswithcommercialinstitutionsthathaveat leastanaorequivalentcreditratingasofdecemberthecompanyhadnotionalamountsoutstandingfor forwardforeignexchangecontractsandcrosscurrencyinterestrateswapsofbillionandbillionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateintothederivativecontractatinceptionallderivatives areexpectedtobehighlyeffectivechangesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearnings andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransactiongainslossesonnetinvestment hedgesareaccountedforthroughthecurrencytranslationaccountandareinsignificantonanongoingbasisthe companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesinthecashflowsof hedgeditemsifandwhenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinued hedgeineffectivenessifanyisincludedincurrentperiodearningsinotherincomeexpensenet asofdecemberthebalanceofdeferrednetgainsonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountrelatedtoforeignexchangecontractswillbe johnsonjohnsonannualreportreclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthatperiod themaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexcludinginterest rateswapstheamountultimatelyrealizedinearningswilldifferasforeignexchangerateschangerealizedgainsand lossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative thefollowingtableisasummaryoftheactivityrelatedtodesignatedderivativesforthefiscalyearsendeddecember andjanuary gainloss gainloss gainloss reclassifiedfrom recognizedin recognizedin accumulatedoci cashflowhedgesbyincomestatementcaption accumulatedoci intoincome incomeexpense dollarsinmillions salestocustomers costofproductssold researchanddevelopmentexpense interestincomeinterestexpensenet otherincomeexpensenet total allamountsshowninthetableabovearenetoftax effectiveportion ineffectiveportion foreignexchangecontracts crosscurrencyinterestrateswaps forthefiscalyearsendeddecemberandjanuaryagainofmillionandalossofmillion respectivelywasrecognizedinotherincomeexpensenetrelatingtoforeignexchangecontractsnotdesignatedas hedginginstruments fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbased measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitythe authoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thefairvalueofaderivativefinancialinstrumentieforwardexchangecontractcurrencyswapistheaggregationby currencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesandsubsequently convertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethatfairvaluesof thesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementormaturityorthat thechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition thecompanyalsoholdsequityinvestmentsthatareclassifiedaslevelastheyaretradedinanactiveexchangemarket thecompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequirerevisedvaluationsunder thisstandardthatarerecognizedatfairvalue thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilities levelsignificantotherobservableinputs levelsignificantunobservableinputs johnsonjohnsonannualreport thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofdecemberandjanuary wereasfollows dollarsinmillions level level level total total derivativesdesignatedashedginginstruments assets foreignexchangecontracts crosscurrencyinterestrateswaps total liabilities foreignexchangecontracts crosscurrencyinterestrateswaps total derivativesnotdesignatedashedginginstruments assets foreignexchangecontracts swissfrancoption total liabilities foreignexchangecontracts otherinvestments assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofotherinvestmentsofmillionwhichareclassified aslevel includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingdecemberandjanuary respectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingdecemberandjanuary respectivelycrosscurrencyinterestrateswapsrelatedtooutstandingeurandgbpnotesmaturedinnovembertheswaps weresettledatfairmarketvalueandreplacedwithnewswaps currencyoptionrelatedtotheacquisitionofsynthesincwhichexpiredinjanuary classifiedasnoncurrentotherassets seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowings thecomponentsoflongtermdebtareasfollows effective effective dollarsinmillions rate rate debenturesdue notesdue debenturesdue monthliborfrndue monthliborfrndue notesdue notesdue debenturesdue debenturesdue notesduebeurobeuro zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue debenturesdue notesduemmgbpmmgbp notesdue debenturesdue notesdue debenturesdue debenturesdue notesdue lesscurrentportion weightedaverageeffectiverate translationrateatdecember translationrateatjanuary theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninandbillionin fairvalueofthenoncurrentdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerprices andsignificantotherobservableinputs thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfees undertheagreementsarenotmaterial throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogramtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiaries thecompanyhasashelfregistrationwiththeussecuritiesandexchangecommissionthatenablesthecompanyto issuedebtsecuritiesandwarrantstopurchasedebtsecuritiesonatimelybasis johnsonjohnsonannualreport aggregatematuritiesoflongtermobligationscommencinginare dollarsinmillions incometaxes theprovisionfortaxesonincomeconsistsof dollarsinmillions currentlypayable ustaxes internationaltaxes totalcurrentlypayable deferred ustaxes internationaltaxes totaldeferred provisionfortaxesonincome acomparisonofincometaxexpenseattheusstatutoryrateofinandtothecompanys effectivetaxrateisasfollows dollarsinmillions us international earningsbeforetaxesonincome taxrates usstatutoryrate internationaloperationsexcludingireland irelandandpuertoricooperations researchandorphandrugtaxcredits usstateandlocal usmanufacturingdeduction ustaxoninternationalincome allother effectivetaxrate includesusexpensesnotfullytaxdeductibleprimarilyrelatedtolitigationexpense theincreaseintheeffectivetaxrateascomparedtowasduetolowertaxbenefitsontheimpairmentofin processresearchanddevelopmentintangibleassetsinlowtaxjurisdictionsincreasesintaxableincomeinhighertax jurisdictionsrelativetolowertaxjurisdictionsandtheexclusionofthebenefitoftheusresearchdevelopmentrd taxcreditandthecfclookthroughprovisionsfromthefiscalyearfinancialresultstherdtaxcreditandthecfc lookthroughprovisionswereenactedintolawinandwereretroactivetojanuarytheentirebenefitofthe rdtaxcreditandthecfclookthroughprovisionswillbereflectedinthefiscalyearfinancialresultstheincrease inthetaxrateascomparedtowasprimarilyduetocertainusexpenseswhicharenotfullytaxdeductible andhigherusstatetaxespartiallyoffsetbyincreasesintaxableincomeinlowertaxjurisdictionsrelativetohighertax jurisdictions johnsonjohnsonannualreporttemporarydifferencesandcarryforwardsforandwereasfollows deferredtax deferredtax dollarsinmillions asset liability asset liability employeerelatedobligations stockbasedcompensation depreciation nondeductibleintangibles internationalrdcapitalizedfortax reservesliabilities incomereportedfortaxpurposes netoperatinglosscarryforwardinternational miscellaneousinternational miscellaneousus totaldeferredincometaxes thedifferencebetweenthenetdeferredtaxonincomeperthebalancesheetandthenetdeferredtaxaboveisincludedin taxesonincomeonthebalancesheetthecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenet lossesthecompanybelievesthatitismorelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincome sufficienttoutilizethesedeferredtaxassets thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits dollarsinmillions beginningofyear increasesrelatedtocurrentyeartaxpositions increasesrelatedtopriorperiodtaxpositions decreasesrelatedtopriorperiodtaxpositions settlements lapseofstatuteoflimitations endofyear theunrecognizedtaxbenefitsofbillionatdecemberifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits inprogresswithanumberoftaxauthoritiestheusinternalrevenueserviceirshascompleteditsauditforthetax yearsthroughhowevertherearealimitednumberofissuesremainingopenforpriortaxyearsgoingbackto inothermajorjurisdictionswherethecompanyconductsbusinesstheyearsremainopengenerallybacktotheyear thecompanybelievesitispossiblethatauditsmaybecompletedbytaxauthoritiesinsomejurisdictionsoverthe nexttwelvemonthshoweverthecompanyisnotabletoprovideareasonablyreliableestimateofthetimingofanyother futuretaxpaymentsrelatingtouncertaintaxpositions thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilities interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany recognizedaftertaxinterestofmillionexpensemillionexpenseandmillionincomeinand respectivelythetotalamountofaccruedinterestwasmillionandmillioninandrespectively johnsonjohnsonannualreport employeerelatedobligations attheendofandemployeerelatedobligationsrecordedontheconsolidatedbalancesheetswere dollarsinmillions pensionbenefits postretirementbenefits postemploymentbenefits deferredcompensation totalemployeeobligations lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheets pensionsandotherbenefitplans thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependents manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant retirementplanbenefitsareprimarilybasedontheemployeescompensationduringthelastthreetofiveyearsbefore retirementandthenumberofyearsofserviceinternationalsubsidiarieshaveplansunderwhichfundsaredepositedwith trusteesannuitiesarepurchasedundergroupcontractsorreservesareprovided thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture thecompanyusesthedateofitsconsolidatedfinancialstatementsdecemberandjanuary respectivelyasthemeasurementdateforallusandinternationalretirementandotherbenefitplans netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponents retirementplans otherbenefitplans dollarsinmillions servicecost interestcost expectedreturnonplanassets amortizationofpriorservicecostcredit amortizationofnettransitionobligation recognizedactuariallosses curtailmentsandsettlements netperiodicbenefitcost amountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearforthecompanysdefinedbenefit retirementplansandotherpostretirementplans dollarsinmillions amortizationofnettransitionobligation amortizationofnetactuariallosses amortizationofpriorservicecost johnsonjohnsonannualreportunrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgains andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheprojectedbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridorareamortizedover theaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheremainingfutureserviceofplanparticipants atthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedovertheaverage remainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment theweightedaverageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalue ofprojectedbenefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear retirementplans otherbenefitplans worldwidebenefitplans discountrate expectedlongtermrateofreturnonplanassets rateofincreaseincompensationlevels thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilities theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsources longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividuals healthcareplans healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate aonepercentagepointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillions pointincrease pointdecrease healthcareplans totalinterestandservicecost postretirementbenefitobligation johnsonjohnsonannualreport thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplans otherbenefit retirementplans plans dollarsinmillions changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontributions amendments actuariallosses divestituresacquisitions curtailmentssettlementsrestructuring benefitspaidfromplan effectofexchangerates projectedbenefitobligationendofyear changeinplanassets planassetsatfairvaluebeginningofyear actualreturnlossonplanassets companycontributions planparticipantcontributions settlements divestituresacquisitions benefitspaidfromplanassets effectofexchangerates planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowing noncurrentassets currentliabilities noncurrentliabilities totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowing netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffects accumulatedbenefitobligationsendofyear changesinplanassetsandbenefitobligationsrecognizedinother comprehensiveincome netperiodicbenefitcost netactuarialloss amortizationofnetactuariallossgain priorservicecost amortizationofpriorservicecostcredit effectofexchangerates totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome johnsonjohnsonannualreportthecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticeas fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunded inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplans respectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberandjanuaryrespectively usplans internationalplans qualifiedplans nonqualifiedplans fundedplans unfundedplans dollarsinmillions planassets projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillions projectedfuturebenefitpayments retirementplans otherbenefitplansgross medicarerebates otherbenefitplansnet thefollowingtabledisplaystheprojectedfutureminimumcontributionstothecompanysusandinternationalunfunded retirementplanstheseamountsdonotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthe future dollarsinmillions projectedfuturecontributions unfundedusretirementplans unfundedinternationalretirementplans eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicles separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretirees durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplans permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefunds johnsonjohnsonannualreport thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follows percentof target planassets allocation worldwideretirementplans equitysecurities debtsecurities totalplanassets determinationoffairvalueofplanassets theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquoted marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilities equityordebtpricesforeignexchangeratesandcreditcurves whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamountheld ondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenetassetvalue navprovidedbytheadministratorofthefundthenavisbasedonthevalueoftheunderlyingassetsownedbythe fundminusitsliabilitiesandthendividedbythenumberofsharesoutstandingthenavisaquotedpriceinamarket thatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified aslevelleveldebtinstrumentsarepricedbasedonunobservableinputs equitysecuritiescommonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallcommonstockisclassifiedwithinlevelofthevaluationhierarchy commingledfundstheinvestmentsarepublicinvestmentvehiclesvaluedusingthenavprovidedbythefund administratorthenavisbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthen dividedbythenumberofsharesoutstandingassetsinthelevelcategoryhaveaquotedmarketpriceinamarketthat isnotactive insurancecontractstheinstrumentsareissuedbyinsurancecompaniesthefairvalueisbasedonnegotiatedvalue andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe issuertheunderlyinginvestmentsaregovernmentassetbackedandfixedincomesecuritiesingeneralinsurance contractsareclassifiedaslevelastherearenoquotedpricesnorotherobservableinputsforpricing johnsonjohnsonannualreport otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestmentsaswellas commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebtotherassetsthatareexchange listedandactivelytradedareclassifiedaslevelwhileinactivelytradedassetsareclassifiedaslevelmostlimited partnershipsrepresentinvestmentsinprivateequityandsimilarfundsthatarevaluedbythegeneralpartnerstheseas wellasanyotherassetsvaluedusingunobservableinputsareclassifiedaslevel thefollowingtablesetsforththeretirementplanstrustinvestmentsmeasuredatfairvalueasofdecemberand january quotedprices significant inactive significant marketsfor observable unobservable identicalassets inputs inputs level level level totalassets dollarsinmillions shortterminvestmentfunds governmentandagencysecurities debtinstruments equitysecurities commingledfunds insurancecontracts otherassets trustinvestmentsatfairvalue thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberandjanuaryrespectivelyandmillionofusshortterminvestmentfunds levelatdecember thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatjanuary levelgainsandlosses thetablebelowsetsforthasummaryofchangesinthefairvalueoftheplanslevelassetsfortheyearsended decemberandjanuary debt equity commingled insurance total dollarsinmillions instruments securities funds contracts assets level balancejanuary realizedgainslosses unrealizedgainslosses purchasessalesissuancesandsettlementsnet balancejanuary realizedgainslosses unrealizedgainslosses purchasessalesissuancesandsettlementsnet balancedecember johnsonjohnsonannualreport savingsplan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninandrespectively capitalandtreasurystock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousands shares amount balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans issuanceofcommonstockassociatedwiththeacquisitionofsynthesinc repurchaseofcommonstock balanceatdecember aggregatesharesofcommonstockissuedwereapproximatelysharesattheendofand cashdividendspaidwerepershareincomparedwithdividendsofpershareinandper sharein includesrepurchaseofcommonstockassociatedwiththeacquisitionofsynthesinc accumulatedothercomprehensiveincome componentsofothercomprehensiveincomelossconsistofthefollowing gains total gains losses accumulated foreign losses employee currency benefit derivatives comprehensive dollarsinmillions translation securities plans hedges incomeloss january netchanges january netchanges january netchanges december amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxesasitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome johnsonjohnsonannualreport internationalcurrencytranslation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyears orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulated othercomprehensiveincomethisequityaccountincludestheresultsoftranslatingallbalancesheetassetsandliabilities atcurrentexchangeratesexceptforthoselocatedinhighlyinflationaryeconomiesthetranslationofbalancesheet accountsforhighlyinflationaryeconomiesarereflectedintheoperatingresults arollforwardofthechangesduringandforforeigncurrencytranslationadjustmentsisincludedin note netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillionand millioninandrespectively earningspershare thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended decemberjanuaryandjanuary inmillionsexceptpershareamounts basicnetearningspershareattributabletojohnsonjohnson averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplans lesssharesrepurchasedundertreasurystockmethod convertibledebtshares acceleratedsharerepurchaseprogram adjustedaveragesharesoutstandingdiluted dilutednetearningspershareattributabletojohnsonjohnson thedilutednetearningspersharecalculationincludesthedilutiveeffectofconvertibledebtthatisoffsetbytherelated reductionininterestexpenseofmillionaftertaxforyearsand dilutednetearningspershareexcludesmillionmillionandmillionsharesunderlyingstockoptionsfor andrespectivelyastheexercisepriceoftheseoptionswasgreaterthantheiraveragemarketvaluewhich wouldresultinanantidilutiveeffectondilutedearningspershare thedilutedearningspersharecalculationforthefiscalyearendeddecemberincludedthedilutiveeffectof millionsharesrelatedtotheacceleratedsharerepurchaseprogramassociatedwiththeacquisitionofsynthesinc seenotetotheconsolidatedfinancialstatementsforadditionaldetailsaincreasedecreaseinthevolume weightedaveragesharepricewouldimpactthisestimatebyapproximatelymillionshares rentalexpenseandleasecommitments rentalsofspacevehiclesmanufacturingequipmentandofficeanddataprocessingequipmentunderoperatingleases wereapproximatelymillionmillionandmillioninandrespectively theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnoncancelable leasetermsinexcessofoneyearatdecemberare dollarsinmillions total commitmentsundercapitalleasesarenotsignificant johnsonjohnsonannualreport commonstockstockoptionplansandstockcompensationagreements atdecemberthecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontracts underthecompanysstockoptionplanthelongtermincentiveplanthelongtermincentiveplan andthesciosincstockoptionplansthelongtermincentiveplanexpiredaprilalloptionsand restrictedsharesgrantedsubsequenttothatdatewereunderthelongtermincentiveplan thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforandrespectivelythetotalincometaxbenefitrecognizedintheincomestatementforshare basedcompensationcostswasmillionmillionandmillionforandrespectivelythe totalunrecognizedcompensationcostwasmillionmillionandmillionforand respectivelytheweightedaverageperiodforthiscosttoberecognizedwasyearsyearsandyearsfor andrespectivelysharebasedcompensationcostscapitalizedaspartofinventorywereinsignificant inallperiods stockoptions stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrantunderthelongtermincentiveplanthecompanymayissueuptomillion sharesofcommonstockplusanysharescanceledexpiredforfeitedornotissuedfromthelongtermincentive plansubsequenttoaprilsharesavailableforfuturegrantsunderthelongtermincentiveplanwere millionattheendof thecompanysettlesemployeestockoptionexerciseswithtreasurysharespreviouslytreasuryshareswerereplenished throughouttheyearforthenumberofsharesusedtosettleemployeestockoptionexerciseshoweverpursuanttothe acceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofsynthesincthecompanyhasnotmade anypurchasesofcommonstockontheopenmarketduringthefiscalthirdandfourthquartersof thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableexpectedvolatilityrepresentsablendedrateofyeardaily historicalaveragevolatilityrateandaweekaverageimpliedvolatilityratebasedonatthemoneytradedjohnson johnsonoptionswithalifeofyearshistoricaldataisusedtodeterminetheexpectedlifeoftheoptiontheriskfreerate wasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinandrespectivelythefair valuewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyears dividendyield johnsonjohnsonannualreportasummaryofoptionactivityundertheplanasofdecemberjanuaryandjanuaryandchanges duringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weighted value outstanding average dollarsin sharesinthousands shares exerciseprice millions sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatdecember thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninand respectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatdecember sharesinthousands outstanding exercisable average average average exercise exercise exercisepricerange options life price options price averagecontractualliferemaininginyears stockoptionsexercisableatjanuaryandjanuarywereatanaveragepriceofandan averagelifeofyearsandatanaveragepriceofandanaveragelifeofyearsrespectively restrictedshareunitsandperformance shareunits thecompanygrantsrestrictedshareunitswithavestingperiodofthreeyearsthecompanyalsograntsperformance shareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockaftertheendofathreeyearperformance periodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistiedtotheachievementoverathree yearperiodofthreeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnsales adjustedoperationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearnedatthe endofthethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberof performanceshareunitsgranted thecompanysettlesemployeestockissuanceswithtreasurysharespreviouslytreasuryshareswerereplenished throughouttheyearforthenumberofsharesusedtosettleemployeestockissuanceshoweverpursuanttothe acceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofsynthesincthecompanyhasnotmade anypurchasesofcommonstockontheopenmarketduringthefiscalthirdandfourthquartersof johnsonjohnsonannualreport asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofdecemberis presentedbelow outstanding outstanding restricted performance sharesinthousands shareunits shareunits sharesatjanuary granted issued canceledforfeited sharesatjanuary granted issued canceledforfeited sharesatjanuary granted issued canceledforfeited sharesatdecember theaveragefairvalueoftherestrictedshareunitsgrantedwasandinand respectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswasdiscountedfor dividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueofrestrictedshareunits settledwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitswasincalculatedusingtheweighted averagefairmarketvalueforeachofthethreecomponentgoalsatthedateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelnoperformanceshare unitswereissuedin segmentsofbusinessandgeographicareas salestocustomers dollarsinmillions consumer unitedstates international total pharmaceutical unitedstates international total medicaldevicesanddiagnostics unitedstates international total worldwidetotal johnsonjohnsonannualreportpretaxprofit identifiableassets dollarsinmillions consumer pharmaceutical medicaldevicesanddiagnostics total lessexpensenotallocatedtosegments generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumer pharmaceutical medicaldevicesanddiagnostics segmentstotal generalcorporate worldwidetotal salestocustomers longlivedassets dollarsinmillions unitedstates europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedassets worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperates exportsalesarenotsignificantinandthecompanydidnothaveacustomerthatrepresentedoftotalrevenues amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincome expenseincludesexpenseofbillionandbillionofcurrencyrelatedexpenserelatedtotheacquisitionofsynthesincin andrespectively generalcorporateincludescashandmarketablesecurities includesmillionofnetlitigationexpensewhichincludesproductliabilitycomprisedofmillionandmillioninthe pharmaceuticalandmedicaldevicesanddiagnosticssegmentsrespectivelyincludesmillionofinprocessresearchand developmentexpensecomprisedofmillionandmillioninthepharmaceuticalandmedicaldevicesanddiagnostics segmentsrespectivelyincludesmillionofsynthesintegrationtransactioncostsinthemedicaldevicesanddiagnostics segmentincludesmillionofassetwritedownsandotheradjustmentscomprisedofmillionmillionand millioninthepharmaceuticalconsumerandmedicaldevicesanddiagnosticssegmentsrespectivelythemedicaldevicesand diagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhipprogram includesmillionofnetlitigationexpensewhichincludesproductliabilitycomprisedofmillionandmillionin thepharmaceuticalandmedicaldevicesanddiagnosticssegmentsrespectivelyincludesmillionofnetrestructuringexpense comprisedofmillionexpenseinthemedicaldevicesanddiagnosticssegmentandagainofmillioninthepharmaceutical segmentthemedicaldevicesanddiagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuy asrhipprogram includesmillionofnetlitigationgainwhichincludesproductliabilityexpensecomprisedofmillionexpenseinthe pharmaceuticalsegmentandagainofmillioninthemedicaldevicesanddiagnosticssegmentthemedicaldevicesand diagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhipprogram longlivedassetsincludepropertyplantandequipmentnetforandofand respectivelyandintangibleassetsandgoodwillnetforandofandrespectively johnsonjohnsonannualreport selectedquarterlyfinancialdataunaudited selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow dollarsinmillionsexceptpershare first second third fourth first second third fourth data quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomers consumer pharmaceutical meddevicesdiagnostics totalsales grossprofit earningsbeforeprovisionfortaxeson income netearningsattributabletojohnson johnson basicnetearningspershareattributable tojohnsonjohnson dilutednetearningspershare attributabletojohnsonjohnson thefirstquarterofincludesanaftertaxgainofmillionfromcurrencyandcostsassociatedwiththeacquisitionof synthesinc thesecondquarterofincludesaftertaxchargesofmillionforassetwritedownsmillionfromnetlitigation millionassociatedwiththeacquisitionofsynthesincandmillionfromimpairmentofinprocessresearchanddevelopment thethirdquarterofincludesaftertaxchargesofmillionassociatedwiththeacquisitionofsynthesincmillion fromimpairmentofinprocessresearchanddevelopmentmillionassociatedwithlitigationincludingproductliabilityand millionassociatedwiththedepuyasrhipprogram thefourthquarterofincludesaftertaxchargesofmillionfromnetlitigationincludingproductliabilitymillion associatedwiththeacquisitionofsynthesincmillionassociatedwiththedepuyasrhipprogramandmillionfrom impairmentofinprocessresearchanddevelopment thefirstquarterofincludesanaftertaxchargeofmillionfromnetlitigationincludingproductliabilityandthedepuy asrhipprogram thesecondquarterofincludesaftertaxchargesofmillionforrestructuringmillionfromlitigationincludingproduct liabilityandthedepuyasrhipprogrampartiallyoffsetbyamillionaftertaxgainassociatedwithanadjustmenttothevalue ofthecurrencyoptionrelatedtotheacquisitionofsynthesinc thethirdquarterofincludesamillionaftertaxchargeassociatedwithanadjustmenttothevalueofthecurrencyoption anddealcostsrelatedtotheacquisitionofsynthesinc thefourthquarterofincludesaftertaxchargesofmillionfromnetlitigationincludingproductliabilitymillionfor thecostassociatedwiththedepuyasrhipprogramandmillionassociatedwithanadjustmenttothevalueofthecurrency optionanddealcostsrelatedtotheacquisitionofsynthesinc businesscombinationsanddivestitures certainbusinesseswereacquiredformillionincashandstockandmillionofliabilitiesassumedduring theseacquisitionswereaccountedforbythepurchasemethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedsynthesincaglobaldeveloperandmanufactureroforthopaedicsdevicesguangzhou biosealbiotechcoltdadeveloperofbiologiccombinationsaddressingmoderatetoseverehemostasisangiotech pharmaceuticalsincintellectualpropertyandknowhowrelatedtothequillknotlesstissueclosuredevicecorlmmun incadeveloperofaphaseiitreatmentforchfcalibramedicalincdeveloperofauniquewearablethreedayinsulin patchforconvenientanddiscreetmealtimedosingforpeoplewithdiabeteswhotakemultipledailyinjectionsofinsulin spectrumvisionllcafullservicedistributorofcontactlensesservingrussiawithfacilitiesintheukraineand kazakhstanmarketingauthorizationstrademarksandpatentsextendingzyrtecrelatedmarketrightsinaustraliaand canada johnsonjohnsonannualreporttheexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionand hasbeenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionsofcorlmmunincand synthesinc theiprdrelatedtotheacquisitionofsynthesincofmillionisassociatedwithorthopaedicdevicesandtheiprd associatedwithcorlmmunofmillionisrelatedtoachftreatmenttheseiprdvalueswerecalculatedusingthe cashflowprojectionsdiscountedfortheriskinherentinsuchprojectssynthesinchadaprobabilityofsuccessfactorof discountedusingaratecorlmmunhadaprobabilityofsuccessfactorofdiscountedusingarate duringthefiscalsecondquarterthecompanycompletedtheacquisitionofsynthesincaglobaldeveloperand manufactureroforthopaedicsdevicesforapurchasepriceofbillionincashandstockthenetacquisitioncostof thetransactionisbillionbasedoncashonhandatclosingofbillion underthetermsoftheagreementeachshareofsynthesinccommonstockwasexchangedforchfincashand sharesofjohnsonjohnsoncommonstockbasedonthecalculatedexchangeratiotheexchangeratiowas calculatedonjuneandbasedontherelevantexchangerateandclosingpriceofjohnsonjohnsoncommon stockonthatdatethetotalfairvalueofconsiderationtransferredwasbillionwhentheacquisitionwascompleted onjunebasedontherelevantexchangerateandclosingpriceofjohnsonjohnsoncommonstockonthat datethetotalfairvalueoftheconsiderationtransferredwasbillionjanssenpharmaceuticalacompanyorganized underthelawsofirelandandawhollyownedsubsidiaryofjohnsonjohnsonusedcashonhandtosatisfythecash portionofthemergerconsideration thestockportionofthemergerconsiderationconsistedofsharesofjohnsonjohnsoncommonstockpurchasedby janssenpharmaceuticalfromtwobankspursuanttotwoacceleratedsharerepurchaseasragreementsdated juneonjunejanssenpharmaceuticalpurchasedanaggregateofapproximatelymillionshares ofjohnsonjohnsoncommonstockataninitialpurchasepriceofbillionundertheasragreementswithallofthe sharesdeliveredtojanssenpharmaceuticalonjunefinalsettlementofthetransactionsundereachasr agreementisexpectedtooccurinthefirsthalfofandmayoccurearlierattheoptionofthetwobanksas applicableorlaterundercertaincircumstancesbasedonthetheoreticalsettlementoftheasragreementsanadditional millionshareswouldbeissuedtosettletheasragreementsasofdecember inadditionwhilethecompanybelievesthatthetransactionsundereachasragreementandaseriesofrelatedinternal transactionswereconsummatedinataxefficientmannerinaccordancewithapplicablelawitispossiblethattheinternal revenueservicecouldassertoneormorecontrarypositionstochallengethetransactionsfromataxperspectiveif challengedanamountuptothetotalpurchasepriceforthesynthessharescouldbetreatedassubjecttoapplicableus taxatapproximatelythestatutoryratetothecompanyplusinterest thefollowingtablesummarizestheconsiderationtransferredtoacquiresynthesincvaluedontheacquisitiondateof june dollarsinmillions cashmultiplychfbysharesofsynthescommonstockoutstandingbytheexchangeratea commonstockmultiplybysharesofsynthescommonstockoutstandingbyjjstockpriceb totalfairvalueofconsiderationtransferred synthescommonstockoutstandingofmillionsharesasoftheacquisitiondateandchfusdexchangerateof b johnsonjohnsonclosingstockpriceonthenewyorkstockexchangeasofacquisitiondateofpershare thecompanyisstillfinalizingtheallocationofthepurchasepricetotheindividualassetsacquiredandliabilitiesassumed theallocationofthepurchasepriceincludedinthecurrentperiodbalancesheetisbasedonthebestestimateof managementtoassistmanagementintheallocationthecompanyengagedvaluationspecialiststoprepareindependent appraisalscertainestimatedvaluessurroundinglitigationlosscontingenciesarenotyetfinalizedandaresubjectto changewewillfinalizetheamountsrecognizedasweobtaintheinformationnecessarytocompletetheanalysiswe expecttofinalizetheseamountsassoonaspossiblebutnolaterthanoneyearfromtheacquisitiondate johnsonjohnsonannualreport thefollowingtablepresentstheamountsrecognizedforassetsacquiredandliabilitiesassumedasoftheacquisitiondate aswellastheadjustmentsmadeuptodecember dollarsinmillions june december cashcashequivalents inventory accountsreceivablenet othercurrentassets propertyplantandequipment goodwill intangibleassets othernoncurrentassets totalassetsacquired currentliabilities deferredtaxes othernoncurrentliabilities totalliabilitiesassumed netassetsacquired theadjustmentsmadesincethedateofacquisitionweretoaccountforchangestoinventorybasedontheresultsofthe physicalinventorycountsanddeferredtaxestoreflectthestatutorytaxratethatisbeingappliedtotheintangibleassets therevisionstothepurchasepriceallocationwerenotmaterialtothestatementsofconsolidatedearningsfortheprior fiscalquartersof theassetsacquiredarerecordedinthemedicaldevicesanddiagnosticssegmenttheacquisitionofsynthesinc resultedinbillionofgoodwillthegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromtheacquisition ofsynthesincthegoodwillisnotexpectedtobedeductiblefortaxpurposes thepurchasepriceallocationtotheidentifiableintangibleassetsincludedinthejuneanddecember balancesheetswereasfollows dollarsinmillions june december intangibleassetswithdefinitelives customerrelationships patentsandtechnology totalamortizableintangibles trademarkandtradename inprocessresearchanddevelopment totalintangibleassets theweightedaveragelifeforthebillionoftotalamortizableintangiblesisapproximatelyyears thetradenameassetvaluesweredeterminedtohaveanindefinitelifebasedonanumberoffactorsincludingtradename historythecompetitiveenvironmentmarketshareandfutureoperatingplanstheintangibleassetswithdefiniteliveswere assignedassetlivesrangingfromtoyears themajorityoftheintangibleassetvaluationrelatestocustomerrelationshipspatentsandtechnologyandtradename intangibleassetsinthecompanystraumacraniomaxillofacialspineandpowertoolsbusinesslinesadditionallyin processresearchanddevelopmentintangibleassetswerevaluedfortechnologyprogramsforunapprovedproducts thevalueoftheiprdwascalculatedusingcashflowprojectionsdiscountedfortheriskinherentinsuchprojectsthe discountrateappliedwas thecompanyisintheprocessofexecutingtheintegrationplanstocombinebusinessessalesorganizationssystems andlocationsasaresultofwhichthecompanyhasandwillcontinuetoincurintegrationcosts johnsonjohnsonannualreporttheoperatingresultsofsyntheswerereportedinthecompanysfinancialstatementsbeginningonjunetotal salesandnetearningsforsynthesforthefiscalyearendeddecemberweremillionandmillion respectively thefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendeddecemberandjanuary asifsynthesinchadbeenacquiredasofjanuarytheproformaresultsincludetheeffectofdivestitures andcertainpurchaseaccountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseon theacquiredtangibleandintangibleassetshoweverproformaresultsdonotincludeanyanticipatedcostsavingsor othereffectsoftheintegrationofsynthesincaccordinglysuchamountsarenotnecessarilyindicativeoftheresultsifthe acquisitionhadoccurredonthedatesindicatedorwhichmayoccurinthefuture unauditedproforma consolidatedresults dollarsinmillionsexceptpershareamounts netsales netearningsattributabletojohnsonjohnson dilutednetearningspershareattributabletojohnsonjohnson inthecompanyrecordedacquisitionrelatedcostsofmillionbeforetaxwhichwererecordedincostof productssoldandotherincomeexpense inconnectionwiththesynthesacquisitiondepuyorthopaedicsincagreedtodivestcertainrightsandassetsrelatedto itstraumabusinesstobiometincandcompletedtheinitialclosingforthistransactioninthefiscalsecondquarterof includingthosecountriesthatrepresentedthemajorityofsalesasofdecemberthetransactionhad closedworldwide certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforbythepurchasemethodandaccordinglyresultsofoperationshavebeenincludedinthe financialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedcrucellnvaglobalbiopharmaceuticalcompanyfocusedontheresearch developmentproductionandmarketingofvaccinesandantibodiesagainstinfectiousdiseaseworldwidetheoverthe counterbrandsofjbchemicalspharmaceuticalslimitedincludingrinzarussiasleadingmultisymptomcough andcoldbrandanddoktormomrussiasnumbertwosellingcoughbrandaswellasseveralotherbrandsfull ownershipofthejohnsonjohnsonmerckconsumerpharmaceuticalscojointventureintheusfrommercksharp dohmecorpandsterilmedincaleaderinthereprocessingandremanufacturingofmedicaldevicesintheus theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionofcrucellnv theiprdrelatedtotheacquisitionofcrucellnvofmillionisassociatedwithvaccinesandantibodiesthat preventandortreatinfectiousdiseasesthevalueoftheiprdwascalculatedusingcashflowprojectionsdiscounted fortheriskinherentinsuchprojectsprobabilityofsuccessfactorsrangingfromwereusedtoreflectinherent clinicalandregulatoryriskthediscountrateappliedwasduringthefiscalsecondquarterofthecompany recordedachargeofbillionfortheintangibleassetwritedownandbillionfortheimpairmentoftheinprocess researchanddevelopmentrelatedtothecrucellbusiness certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforbythepurchasemethodandaccordinglyresultsofoperationshavebeenincludedinthe financialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedacclarentincaprivatelyheldmedicaltechnologycompanydedicatedtodesigning developingandcommercializingdevicesthataddressconditionsaffectingtheearnoseandthroatentrespivertltda privatelyhelddrugdiscoverycompanyfocusedondevelopingsmallmoleculeinhaledtherapiesforthetreatmentof pulmonarydiseasesandmicrusendovascularllcaglobaldeveloperandmanufacturerofminimallyinvasivedevicesfor hemorrhagicandischemicstroke theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionsofacclarentincrespivertltdand micrusendovascularllc johnsonjohnsonannualreport theiprdrelatedtotheacquisitionofacclarentincwasmillionandisassociatedwithnovelendoscopiccatheter baseddevicestomeettheneedsofentpatientsthevalueoftheiprdwascalculatedusingcashflowprojections discountedfortheriskinherentinsuchprojectsprobabilityofsuccessfactorsrangingfromwereusedto reflectinherentclinicalandregulatoryriskthediscountrateappliedwas theiprdrelatedtotheacquisitionofrespivertltdwasmillionandisassociatedwithnarrowspectrumkinase inhibitorswithauniqueprofileofantiinflammatoryactivitiesastreatmentsformoderatetosevereasthmachronic obstructivepulmonarydiseasecopdandcysticfibrosiscfthevalueoftheiprdwascalculatedusingcashflow projectionsdiscountedfortheriskinherentinsuchprojectsprobabilityofsuccessfactorsrangingfromwere usedtoreflectinherentclinicalandregulatoryriskthediscountrateappliedwas theiprdrelatedtotheacquisitionofmicrusendovascularllcwasmillionandisassociatedwithischemicand flowdivertertechnologiesthevalueoftheiprdwascalculatedusingcashflowprojectionsdiscountedfortherisk inherentinsuchprojectsprobabilityofsuccessfactorsrangingfromwereusedtoreflectinherentclinicaland regulatoryriskthediscountrateappliedwas withtheexceptionofthesynthesincacquisitionsupplementalproformainformationforandin accordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleassetsisnot providedastheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsof operationscashflowsorfinancialposition duringthecompanydivestituresincludedbystolicnebivololiprightstoforestlaboratoriesincthetrauma businessofdepuyorthopaedicsinctobiometincthetherakosbusinesstoanaffiliateofgorescapitalpartnersiii lpthesaleofcertainconsumerbrandsandtherhogambusinessinthegainsonthedivestituresof businesseswerebillionduringthecompanydivestituresincludedtheanimalhealthbusinesstoelancoa divisionofelilillymonistatincanadatheusanditsterritoriesincludingpuertoricoassetsoftheortho dermatologicsdivisionintheustosubsidiariesofvaleantpharmaceuticalsinternationalincandthesurgical instrumentsbusinessofcodmanshurtleffincinthegainsonthedivestituresofbusinesseswerebillion duringthecompanydivestituresincludedthebreastcarebusinessofethiconendosurgeryincthegainson thesedivestitureswererecognizedinotherincomeexpensenet legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount ofthelosscanbereasonablyestimatedasofdecemberthecompanyhasdeterminedthattheliabilities associatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthecompanyhasaccruedfor thesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther developmentsinaccordancewithascfortheseandotherlitigationandregulatorymatterscurrently disclosedforwhichalossisprobableorreasonablypossiblethecompanyisunabletodetermineanestimateofthe possiblelossorrangeoflossbeyondtheamountsalreadyaccruedthesematterscanbeaffectedbyvariousfactors includingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscovery hasnotcommencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiesthereare significantfactsindisputeortherearenumerouspartiesinvolved inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutioninanyreportingperiodofone ormoreofthesematterseitheraloneorintheaggregatemayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod johnsonjohnsonannualreportproductliability certainsubsidiariesofjohnsonjohnsonareinvolvedinnumerousproductliabilitycasesthedamagesclaimedare substantialandwhilethesesubsidiariesareconfidentoftheadequacyofthewarningsandinstructionsforusethat accompanytheproductsatissueitisnotfeasibletopredicttheultimateoutcomeoflitigationthecompanyhas establishedproductliabilityaccrualsincompliancewithascbasedoncurrentlyavailableinformationwhichin somecasesmaybelimitedchangestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomes available multipleproductsofjohnsonjohnsonsubsidiariesaresubjecttoproductliabilityclaimsandlawsuitsinwhichclaimants seeksubstantialcompensatoryandwhereavailablepunitivedamagesincludinglevaquintheasrxlacetabular systemanddepuyasrhipresurfacingsystemthepinnacleacetabularcupsystemrisperdalpelvic meshesduragesicfentanylpatchesandtopamaxasofdecemberintheustherewere approximatelyplaintiffswithdirectclaimsinpendinglawsuitsregardinginjuriesallegedlyduetolevaquin withrespecttotheasrxlacetabularsystemanddepuyasrhipresurfacingsystemwithrespectto thepinnacleacetabularcupsystemwithrespecttorisperdalwithrespecttopelvicmeshes withrespecttoduragesicfentanylpatchesandwithrespecttotopamax inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonandthenumberofpendinglawsuitscontinuestoincreasecasesfiledin federalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtfor thenortherndistrictofohiolitigationhasalsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunited kingdomcanadaandaustraliathecompanycontinuestoreceiveinformationwithrespecttopotentialcostsassociated withthisrecallduringthefiscalthirdandfourthquartersofthecompanyincreaseditsaccrualsforthedepuy asrhiprecallprogramandrelatedproductliabilityafterthecompanycompletedananalysisofnewinformation includingthenumberofexpectedclaimsrecentlyupdatedrevisionratesoftherecalledproductsandproductliability expensepercasechangestotheseaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavealsobeenmadeagainstdepuyandjohnsonjohnsonrelatingtodepuyspinnacle acetabularcupsystemthenumberofpendingproductliabilitylawsuitscontinuestoincreaseandthecompany continuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcasescasesfiledin federalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtfor thenortherndistrictoftexasthecompanyhasestablishedaproductliabilityaccrualinanticipationofproductliability litigationassociatedwithdepuyspinnacleacetabularcupsystemchangestothisaccrualmayberequiredinthe futureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicons pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethenumberofpendingproduct liabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcosts andtheanticipatednumberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamulti districtlitigationintheunitedstatesdistrictcourtforthesoutherndistrictofwestvirginiainadditionaclassaction andseveralindividualpersonalinjurycaseshavebeencommencedincanadaandaustraliaseekingdamagesforalleged injuryresultingfromethiconspelvicmeshdevicesthecompanyhasestablishedaproductliabilityaccrualinanticipation ofproductliabilitylitigationassociatedwithethiconspelvicmeshproductschangestothisaccrualmayberequiredin thefutureasadditionalinformationbecomesavailable thecompanybelievesthattheultimateresolutionofthesemattersbasedonhistoricalandreasonablylikelyfuturetrends isnotexpectedtohaveamaterialadverseeffectonthecompanysfinancialpositionannualresultsofoperationsand cashflowstheresolutioninanyinterimreportingperiodcouldhaveamaterialimpactonthecompanysresultsof operationsandcashflowsforthatperiod johnsonjohnsonannualreport intellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessthemostsignificantofthesematters aredescribedbelow patentinfringement certainsubsidiariesofjohnsonjohnsonareinvolvedinlawsuitschallengingthecoverageandorvalidityofthepatents ontheirproductsalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensestothesechallengeswithrespect toallmaterialpatentstherecanbenoassuranceastotheoutcomeofthesemattersandalossinanyofthesecases couldpotentiallyadverselyaffecttheabilityofthesesubsidiariestoselltheirproductsorrequirethepaymentofpast damagesandfutureroyalties medicaldevicesanddiagnostics inoctobertycohealthcaregrouplptycoandussurgicalcorporationfiledalawsuitagainstethiconendo surgeryinceesintheunitedstatesdistrictcourtforthedistrictofconnecticutallegingthatseveralfeaturesof eessharmonicscalpelinfringedfourtycopatentsinoctoberonmotionsforsummaryjudgmentpriortothe initialtrialanumberofclaimswerefoundinvalidandanumberwerefoundinfringedhowevernoclaimwasfoundboth validandinfringedtrialcommencedindecemberandthecourtdismissedthecasewithoutprejudiceongrounds thattycodidnotownthepatentsinsuitthedismissalwithoutprejudicewasaffirmedonappealinjanuarytyco filedanothercomplaintintheunitedstatesdistrictcourtforthedistrictofconnecticutassertinginfringementofthreeof thefourpatentsfromthepreviouslawsuitandaddingnewproductstycoisseekingmonetarydamagesandinjunctive reliefthecasewastriedinjulyandthepartiesareawaitingadecisionfromthecourt inoctoberbrucesaffransaffranfiledapatentinfringementlawsuitagainstjohnsonjohnsonandcordis corporationcordisintheunitedstatesdistrictcourtfortheeasterndistrictoftexasalleginginfringementonus patentnoinjanuaryajuryreturnedaverdictfindingthatcordisssalesofitscypherstentwillfully infringedthepatentthejuryawardedsaffranmillioninmarchthecourtenteredjudgmentagainst cordisintheamountofmillionrepresentingthejuryverdictplusmillioninprejudgmentinterestcordishas appealedthejudgmentoralargumentwasheardindecemberandadecisionfromthecourtofappealsis pendingbecausethecompanybelievesthatthepotentialforanunfavorableoutcomeisnotprobableithasnot establishedanaccrualwithrespecttothecase innovemberrochediagnosticsoperationsincetalrochefiledapatentinfringementlawsuitagainstlifescan inclifescanintheunitedstatesdistrictcourtforthedistrictofdelawareaccusinglifescansentireonetouchline ofbloodglucosemonitoringsystemsofinfringementoftwopatentsrelatedtotheuseofmicroelectrodesensorsin septemberlifescanobtainedafavorablerulingonclaimconstructionthatprecludedafindingofinfringementthe courtenteredjudgmentagainstrocheinjulyandrocheappealedthecourtofappealsreversedthedistrict courtsrulingonclaimconstructionandremandedthecasetothedistrictcourtfornewfindingsontheissuetheparties areawaitingarulingonclaimconstructionrocheisseekingmonetarydamagesandinjunctiverelief injunerembrandtvisiontechnologieslprembrandtfiledapatentinfringementlawsuitagainstjohnson johnsonvisioncareincjjvcintheunitedstatesdistrictcourtfortheeasterndistrictoftexasallegingthatjjvcs manufactureandsaleofitsacuvueadvanceandacuvueoasyshydrogelcontactlensesinfringetheirus patentnothechangpatentrembrandtisseekingmonetaryreliefthecasewastransferredtotheunited statesdistrictcourtforthemiddledistrictoffloridainmaythejuryreturnedaverdictholdingthatneitherofthe accusedlensesinfringethepatentrembrandthasfiledanappealwiththeunitedstatescourtofappealsforthe federalcircuit innovemberhowmedicaosteonicscorphowmedicaandstrykerirelandltdstrykerfiledapatent infringementlawsuitagainstdepuyorthopaedicsincdepuyintheunitedstatesdistrictcourtforthedistrictofnew jerseyalleginginfringementbydepuyspinnacleacetabularcupsystemandduralocacetabularcupsystemof apatentrelatingtoaduallockingmechanismfeatureinanacetabularcupsystemhowmedicaandstrykerareseeking monetarydamagesandinjunctivereliefdepuyfileditsanswerinfebruaryandfiledacounterclaimassertingthat strykerstridentacetabularhipsysteminfringesdepuysuspatentnodepuyisseekingdamagesand injunctiverelieffromhowmedicaandstryker johnsonjohnsonannualreportinmaymedtronicminimedincmedtronicpuertoricooperationscoandminimeddistributioncorpcollectively medtronicminimedfiledapatentinfringementlawsuitagainstanimascorporationintheunitedstatesdistrictcourtfor thecentraldistrictofcaliforniaallegingthatanimasonetouchpingglucosemanagementsysteminfringesnineof theirpatentsmedtronicminimedisseekingmonetarydamagesandinjunctiverelief injunedepuyorthopaedicsincdepuyfiledadeclaratoryjudgmentactionagainstorthopaedichospitalohin theunitedstatesdistrictcourtforthenortherndistrictofindianaseekingadeclarationofthepartiesrightsand obligationsunderapatentrightsandlicenseagreementbetweenthepartiesrelatedtodevelopmentofapolyethylene materialohhasclaimedthatdepuyowesroyaltiesonproductsmadewithantioxidantpolyethylenedepuydisputesthat itowessuchroyaltiestoohandisthusseekingadeclarationfromthecourtondisputedcontractualprovisionsafter depuyfiledthedeclaratoryjudgmentactionohfiledaseparatesuitonthesamesubjectmatterintheunitedstates districtcourtforthecentraldistrictofcaliforniaandmovedforconsolidationwiththecaliforniacase pharmaceutical inmayabbottbiotechnologyltdabbottfiledapatentinfringementlawsuitagainstcentocorinccentocor nowjanssenbiotechincjbiintheunitedstatesdistrictcourtforthedistrictofmassachusettsallegingthat simponiinfringesabbottsuspatentnosandthesalfeldpatentsabbottisseeking monetarydamagesandinjunctivereliefinaprilthepartiesparticipatedinanarbitrationontheissueofjbis defensethatabbottisequitablyestoppedfromassertingthepatentsinmaythearbitratorrejectedjbisdefense thecasehasbeenreinstatedinthedistrictcourtandfactdiscoveryisongoing inaugustabbottgmbhcoabbottgmbhandabbottbioresearchcenterfiledapatentinfringementlawsuit againstcentocornowjbiintheunitedstatesdistrictcourtforthedistrictofmassachusettsallegingthatstelara infringestwounitedstatespatentsassignedtoabbottgmbhjbifiledacomplaintintheunitedstatesdistrictcourtfor thedistrictofcolumbiaforadeclaratoryjudgmentofnoninfringementandinvalidityoftheabbottgmbhpatentsaswell asacomplaintforreviewofapatentinterferencedecisionthatgrantedpriorityofinventionononeofthetwoasserted patentstoabbottgmbhthecaseshavebeentransferredfromthedistrictofcolumbiatothedistrictofmassachusetts trialwasheldinseptemberwithajuryverdictinfavorofcentocorinvalidatingabbottspatentclaimsposttrial briefinghasbeencompletedandthepartiesareawaitingadecisionalsoinaugustabbottgmbhandabbott laboratorieslimitedbroughtapatentinfringementlawsuitinthefederalcourtofcanadaallegingthatstelara infringesabbottgmbhscanadianpatentatrialisscheduledfordecemberinthecanadiancaseinadditionto theusandcanadianlitigationsinaugustabbottfiledpatentinfringementlawsuitsinthenetherlands switzerlandandgermanyineachoftheabovecasesabbottisseekingmonetarydamagesandinjunctiverelief litigationagainstfilersofabbreviatednewdrugapplicationsandas thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthatfiledabbreviatednewdrugapplications andasseekingtomarketgenericformsofproductssoldbyvarioussubsidiariesofjohnsonjohnsonpriortoexpiration oftheapplicablepatentscoveringthoseproductstheseandastypicallyincludeallegationsofnoninfringement invalidityandunenforceabilityofthesepatentsintheeventthesubsidiariesarenotsuccessfulintheseactionsorthe statutorymonthstaysexpirebeforetheunitedstatesdistrictcourtrulingsareobtainedthethirdpartycompanies involvedwillhavetheabilityuponapprovaloftheunitedstatesfoodanddrugadministrationfdatointroducegeneric versionsoftheproductsatissueresultinginverysubstantialmarketshareandrevenuelossesforthoseproducts concerta anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsofconcertain septemberasettlementagreementwasenteredintowithkremersurbanllcandkudcoirelandltd collectivelykudcopursuanttowhichkudcowasgrantedalicenseunderthepatentinsuittomarketitsgeneric versionofconcertastartingonjulyifandwhenkudcoobtainsfdaapproval innovemberalzacorporationalzaandorthomcneiljanssenpharmaceuticalsincomjpinowjanssen pharmaceuticalsincjpifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof delawareagainstimpaxlaboratoriesincimpaxtevapharmaceuticalsusaincandtevapharmaceuticalindustries ltdcollectivelytevainresponsetoimpaxandtevasfilingofamajoramendmenttoitsandaseekingapprovalto marketagenericversionofconcertabeforetheexpirationofalzaandjpispatentrelatingtoconcertaimpax johnsonjohnsonannualreport andtevafiledcounterclaimsallegingnoninfringementandinvalidityinmayalzaandjpifiledasecondlawsuit againsttevainresponsetotevasfilingofasecondmajoramendmenttoitsandaseekingapprovaltomarketadditional dosagestrengthsofitsgenericconcertaproductbeforetheexpirationofalzaandjpispatentrelatingto concertaineachoftheabovecasesalzaandjpisoughtanorderenjoiningthedefendantsfrommarketingits genericversionofconcertapriortotheexpirationofalzaandjpisconcertapatentinseptembera settlementagreementwasenteredintowithimpaxandtevapursuanttowhichthosepartiesweregrantedalicenseunder thepatentinsuittomarkettheirgenericversionofconcertastartingjulyorearlierundercertain circumstancesifandwhentheyobtainfdaapproval orthotricyclenlo anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsoforthotricyclen loinfebruaryjpiandwatsonlaboratoriesincandwatsonpharmaceuticalsinccollectivelywatsonentered intoasettlementagreementpursuanttothesettlementagreementthepartiesenteredintoasupplyagreementwhereby jpiwillsupplytowatsonacombinationaloralcontraceptivecontainingcertainspecifiedcompoundsfromdecember orearlierundercertaincircumstancesthroughtheexpirationofthepatentondecemberinaddition intheeventwatsondoesnotwishtoexerciseitsrightsunderthesupplyagreementjpihasgrantedwatsonalicenseto marketwatsonsandaproductfromdecemberorearlierundercertaincircumstancesthroughdecember injanuaryomjpinowjpifiledapatentinfringementlawsuitagainstlupinltdandlupinpharmaceuticalsinc collectivelylupinintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetolupinsandaseeking approvaltomarketagenericversionoforthotricyclenlopriortotheexpirationofjpispatentrelatingto orthotricyclenlotheotclopatentlupinfiledacounterclaimalleginginvalidityofthepatenttrial concludedinjuneandinseptemberthecourtissuedadecisioninfavorofjpiinparticularthecourt orderedthattheeffectivedateoftheapprovaloflupinsandawhichhadpreviouslybeenapprovedbenotearlierthan theexpirationoftheotclopatentlupinhasappealedthedecisiontothecourtofappealsforthefederalcircuitoral argumentwasheardinfebruaryandthecourtsdecisionispending innovemberomjpinowjpifiledapatentinfringementlawsuitagainstmylanincandmylanpharmaceuticalsinc collectivelymylanandfamycareltdfamycareintheunitedstatesdistrictcourtforthedistrictofnewjerseyin responsetofamycaresandaseekingapprovaltomarketagenericversionoforthotricyclenlopriortothe expirationoftheotclopatentmylanandfamycarefiledcounterclaimsalleginginvalidityofthepatentinnovember jpiandmylanenteredintoasettlementagreementpursuanttowhichmylanwasgrantedalicenseunderthe otclopatenttomarketitsgenericversionoforthotricyclenlostartingdecemberorearlierunder certaincircumstancesifandwhentheyobtainfdaapproval inoctoberjpifiledapatentinfringementlawsuitagainstsunpharmaglobalfzeandsunpharmaceutical industriescollectivelysunintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetosunsanda seekingapprovaltomarketagenericversionoforthotricyclenlopriortotheexpirationoftheotclopatent inmayjpifiledapatentinfringementlawsuitagainsthauptpharmaincranbaxylaboratorieslimitedand ranbaxyinccollectivelyhauptintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetohaupts andaseekingapprovaltomarketagenericversionoforthotricyclenlopriortotheexpirationoftheotclo patentindecemberjpiandhauptenteredintoasettlementagreementpursuanttowhichhauptwasgranteda licenseundertheotclopatenttomarketitsgenericversionoforthotricyclenlostartingdecember orearlierundercertaincircumstancesifandwhentheyobtainfdaapproval inaugustjpifiledapatentinfringementlawsuitagainstglenmarkgenericsltdandglenmarkgenericsincusa collectivelyglenmarkintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetoglenmarksanda seekingapprovaltomarketagenericversionoforthotricyclenlopriortotheexpirationoftheotclopatent innovemberasettlementagreementwasenteredintowithglenmarkpursuanttowhichglenmarkwasgranteda licenseundertheotclopatenttomarketitsgenericversionoforthotricyclenlostartingdecember orearlierundercertaincircumstancesifandwhentheyobtainfdaapproval ineachoftheabovecasesjpisoughtorisseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsoforthotricylcenlobeforetheexpirationoftheotclopatent johnsonjohnsonannualreportprezista anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsofprezistain novembertibotecincnowtibotecllcandtibotecpharmaceuticalsnowjanssenrdirelandcollectively tibotecfiledapatentinfringementlawsuitagainstlupinltdlupinpharmaceuticalsinccollectivelylupinmylaninc andmylanpharmaceuticalsinccollectivelymylanintheunitedstatesdistrictcourtforthedistrictofnewjerseyin responsetolupinsandmylansrespectiveandasseekingapprovaltomarketgenericversionsoftibotecsprezista productbeforetheexpirationoftibotecspatentrelatingtoprezistalupinandmylaneachfiledcounterclaims allegingnoninfringementandinvalidityinjulytibotecfiledanotherpatentinfringementlawsuitagainstlupininthe unitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetolupinssupplementtoitsandatoaddnew dosagestrengthsforitsproposedproductinaugusttibotecandgdsearlecompanygdsearlefileda patentinfringementlawsuitagainstlupinandmylaninresponsetotheirnoticelettersadvisingthattheirandasare seekingapprovaltomarketgenericversionsoftibotecsprezistaproductbeforetheexpirationoftwopatentsrelating toprezistathattibotecexclusivelylicensesfromgdsearle inmarchtibotecandgdsearlefiledapatentinfringementlawsuitagainsttevapharmaceuticalsusaincand tevapharmaceuticalsltdcollectivelytevaintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponse totevasandaseekingapprovaltomarketagenericversionofprezistabeforetheexpirationofcertainpatents relatingtoprezistathattiboteceitherownsorexclusivelylicensesfromgdsearle inmarchtibotecfiledapatentinfringementlawsuitagainstheterodrugsltdunitiiiandheterousainc collectivelyheterointheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetoheterosanda seekingapprovaltomarketagenericversionofprezistabeforetheexpirationofcertainpatentsrelatingto prezistathattibotecexclusivelylicensesfromgdsearleinjulyuponagreementbythepartiesthecourt enteredastayofthelawsuitpendingafinaldecisioninthelawsuitagainsttevawithrespecttothevalidityandor enforceabilityofthepatentsthattiboteclicensesfromgdsearlewithheteroagreeingtobeboundbysuchfinal decision inseptemberthecourtconsolidatedtheabovelawsuitsaswellaslawsuitsbroughtbytheunitedstates governmentagainsteachofthedefendantsforinfringementofaunitedstatesgovernmentownedpatentrelatingto prezistaforpurposesofpretrialdiscoveryandtrialwiththeprovisothatafterdiscoveryiscompletedanypartycan movetohavethecasesdeconsolidatedfortrial inmayandjunejanssenproductslpandjanssenrdirelandcollectivelyjanssenandgdsearlefileda patentinfringementlawsuitagainstlupintevaandmylanintheunitedstatesdistrictcourtforthedistrictofnewjersey alleginginfringementofnewlyissuedunitedstatesreissuepatentnorewhichjanssenexclusivelylicenses fromgdsearleinaugustjanssenandgdsearlefiledapatentinfringementlawsuitagainstlupintevaand mylanintheunitedstatesdistrictcourtforthedistrictofnewjerseyalleginginfringementofnewlyissuedunitedstates reissuepatentnorewhichjanssenexclusivelylicensesfromgdsearlethesecaseshavebeenconsolidated withtheabovelawsuitsinoctoberjanssenfiledamotiontofileasupplementalcomplaintagainstlupintevaand mylanintheunitedstatesdistrictcourtforthedistrictofnewjerseyalleginginfringementofunitedstatespatentnos mylanonlylupinandtevaonlyandlupinandtevaonlyinjanuarythe courtpermittedthesethreeadditionalpatentstobeaddedtotheconsolidatedaction ineachoftheabovelawsuitstibotecandjanssenareseekinganorderenjoiningthedefendantsfrommarketingtheir genericversionsofprezistabeforetheexpirationoftherelevantpatents otherintellectualpropertymatters inseptembercentocororthobiotechproductslpnowjanssenproductslpjplpintervenedinan inventorshiplawsuitfiledbytheuniversityofkansascenterforresearchinckucragainsttheunitedstatesof americausaintheunitedstatesdistrictcourtforthedistrictofkansaskucrallegesthattwokucrscientists shouldbeaddedasinventorsontwousaownedpatentsrelatingtovelcadetheusalicensedthepatentsand theirforeigncounterpartstomillenniumpharmaceuticalsincmpiwhointurnsublicensedthepatentsandtheirforeign counterpartstojplpforcommercialmarketingoutsidetheunitedstatesinjulythepartiesreachedasettlement agreementtoresolvethedisputesinthiscaseandsubmittedtheinventorshipissuetoarbitrationtheoutcomeofwhich woulddeterminewhetherprespecifiedpaymentswouldbemadetokucrbutwillnotaffectjplpsrighttomarket velcadethearbitrationtookplaceindecemberandadecisioninfavorofkucrwasissuedinmarchas aresultjplpwillberequiredtomaketheaforementionedprespecifiedpaymentstokucr johnsonjohnsonannualreport indecemberthestateofisraelfiledalawsuitinthedistrictcourtintelavivjaffaagainstomrix biopharmaceuticalsincandvariousaffiliatesomrixinthelawsuitthestateclaimsthatanemployeeofagovernment ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe wasagovernmentemployeethestateclaimsthathehadnorighttotransferanyintellectualpropertytoomrixbecauseit belongstothestatethestateisseekingdamagesplusroyaltiesonquixilandevicelproductsoralternatively transferofthepatentstothestate injanuarygenentechincgenentechinitiatedanarbitrationagainstucbcelltechcelltechseekingdamagesfor allegedlycooperatingwithcentocorincnowjanssenbiotechincjbitoimproperlyterminateaprioragreementin whichjbiwassublicensedundergenentechscabillypatentstosellremicadejbihasanindemnityagreementwith celltechandcelltechassertedthatjbiwouldbeliableforanydamagescelltechmayberequiredtopaygenentechinthat arbitrationfollowinganarbitrationhearinginjunethearbitratorsissuedadecisionfindingnoliabilityforcelltech andthereforejbiisnotliableforanypotentialindemnityclaimjbihasmovedtorecoveritsattorneysfeescostsand expenses inmarchnoramcoincnoramcomovedtointerveneinthreepatentinfringementlawsuitsfiledintheunited statesdistrictcourtforthesoutherndistrictofnewyorksdnybypurduepharmalpandotherspurdueagainst noramcooxycodonecustomersimpaxlaboratoriesincimpaxtevapharmaceuticalsusainctevaandamneal pharmaceuticalsllcamnealinfebruarynoramcoappearedonbehalfofnoramcocustomerswatson laboratoriesincfloridaandandrxlabsllccollectivelywatsonandrxinasimilarlawsuitfiledbypurdueinthe sdnythelawsuitsareinresponsetothedefendantsrespectiveandasseekingapprovaltomarketgenericextended releaseoxycodoneproductsbeforetheexpirationofcertainpurduepatentsthreeoftheassertedpatentsrelateto oxycodoneandprocessesformakingoxycodoneandnoramcohasagreedtodefendthelawsuitsonbehalfofimpax tevaamnealandwatsonandrxalthoughnoramcodidnotparticipateinnovemberatrialinalawsuitbroughtby purdueagainstanothernoramcocustomeractaviselizabethllcactavistookplacebecausetheactiveingredientat issueintheactavislawsuitisthesameastheactiveingredientatissueintheabovelawsuitsthedistrictcourtsdecision intheactaviscasemayaffectthoselawsuitsadecisionfromthedistrictcourtintheactaviscaseispending inaugustdrjamesmswansonswansonfiledalawsuitagainstalzacorporationalzainthenorthern districtofcaliforniaseekingtobeaddedasaninventorontwoalzaownedpatentsrelatingto concertaalternativelydrswansonhasallegedthatthepatentsinsuitareinvalidandorunenforceableasaresult ofalzasallegedomissionofdrswansonasanamedinventoronthepatentsdrswansonisseekingdamagesandan awardofunjustenrichmentalzafiledamotiontodismissswansonsclaimsandoralargumentisscheduledforfebruary governmentproceedings likeothercompaniesinthepharmaceuticalandmedicaldevicesanddiagnosticsindustriesjohnsonjohnsonand certainofitssubsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunited statesandothercountriesinwhichtheyoperateasaresultinteractionwithgovernmentagenciesisongoingthemost significantlitigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitispossiblethat criminalchargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsor litigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompaniesaredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct becauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesalepriceawpforthedrugs atissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsmanyofthesecases bothfederalactionsandstateactionsremovedtofederalcourtwereconsolidatedforpretrialpurposesinamultidistrict litigationmdlintheunitedstatesdistrictcourtforthedistrictofmassachusetts theplaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchase ofthedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpinjuneafteratrialonthemeritsthemdlcourtdismissedtheclaimsoftwooftheplaintiffclasses againstthejjawpdefendantsinmarchthecourtdismissedtheclaimsofthethirdclassagainstthejjawp defendantswithoutprejudice johnsonjohnsonannualreportawpcasesbroughtbyvariousattorneysgeneralhaveproceededtotrialagainstothermanufacturersseveralstate casesagainstcertainsubsidiariesofjohnsonjohnsonhavebeensettledincludingkentuckywhichhadbeensetfor trialinjanuaryandkansaswhichhadbeensetfortrialinmarchlouisianaandmississippiaresetfortrialin octoberillinoisissetfortrialinmayandalaskaissetfortrialinjulyotherstatecasesarelikelytobe setfortrialinduecourseinadditionanawpcaseagainstthejjawpdefendantsbroughtbythecommonwealthof pennsylvaniawastriedincommonwealthcourtinoctoberandnovemberthecourtfoundinthe commonwealthsfavorwithregardtocertainofitsclaimsunderthepennsylvaniaunfairtradepracticesandconsumer protectionlawutplenteredaninjunctionandawardedmillioninrestitutionandmillionincivilpenaltiesthe courtfoundinthejjawpdefendantsfavoronthecommonwealthsclaimsofunjustenrichmentmisrepresentation fraudcivilconspiracyandoncertainofthecommonwealthsclaimsundertheutplthejjawpdefendantshave appealedthecommonwealthcourtsutplrulingtothepennsylvaniasupremecourtthecompanybelievesthatthejj awpdefendantshavestrongargumentssupportingtheirappealbecausethecompanybelievesthatthepotentialforan unfavorableoutcomeisnotprobableithasnotestablishedanaccrualwithrespecttotheverdict risperdal injanuaryjanssenpharmaceuticaincjanssenpharmaceuticanowjanssenpharmaceuticalsincjpireceived asubpoenafromtheofficeoftheinspectorgeneraloftheunitedstatesofficeofpersonnelmanagementseeking documentsconcerningsalesandmarketingofanyandallpaymentstophysiciansinconnectionwithsalesandmarketing ofandclinicaltrialsforrisperdalfromtodocumentssubsequenttohavealsobeenrequestedby thedepartmentofjusticeanadditionalsubpoenaseekinginformationaboutmarketingofandadversereactionsto risperdalwasreceivedfromtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniain novembernumeroussubpoenasseekingtestimonyfromvariouswitnessesbeforeagrandjurywerealsoreceived jpicooperatedinrespondingtotheserequestsfordocumentsandwitnessestheunitedstatesdepartmentofjustice andtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniathegovernmentarecontinuingtoactively pursuebothcriminalandcivilactionsinfebruarythegovernmentservedcivilinvestigativedemandsseeking additionalinformationrelatingtosalesandmarketingofrisperdalandsalesandmarketingofinvegathefocusof thesemattersistheallegedpromotionofrisperdalandinvegaforofflabelusesthegovernmenthasnotifiedjpi thattherearealsopendingquitamactionsallegingofflabelpromotionofrisperdalthegovernmentinformedjpi thatitwillinterveneinthesequitamactionsandfileasupersedingcomplaint indiscussionstoresolvecriminalpenaltiesunderthefooddrugandcosmeticactrelatedtothepromotionof risperdalresultedinanagreementinprinciplewiththeunitedstatesattorneysofficefortheeasterndistrictof pennsylvaniaonkeyissuesrelevanttoadispositionofcriminalchargespursuanttoasinglemisdemeanorviolationofthe fooddrugandcosmeticactbutcertainissuesremainopenbeforeasettlementcanbefinalizedduringthe companyaccruedamountstocoverthefinancialcomponentoftheproposedcriminalsettlement inthecompanyalsoreachedanagreementinprinciplewiththeunitedstatesdepartmentofjusticetosettlethree pendingcivilfalseclaimsactmattersthatarependingintheeasterndistrictofpennsylvaniaconcerningsalesand marketingofrisperdalandinvegathenortherndistrictofcaliforniaregardingthesalesandmarketingof natrecordiscussedseparatelybelowandthedistrictofmassachusettsallegingthatthedefendantsprovided theomnicareincomnicarelongtermcarepharmacywithrebatesandotherpaymentsregardingrisperdaland otherproductsdiscussedseparatelybelowassumingtheseagreementsarefinalizedtheywillresolvethefederal governmentsclaimsunderthefederalfalseclaimsactresolveallpendingstateandfederalgovernmentlitigation regardingomnicareandnatrecorandsettletherisperdalmedicaidrelatedclaimsforthosestatesthatoptinto thesettlementwiththetentativesettlementagreementsdescribedaboveissuesremainopenthatmustberesolved beforethesettlementscanbefinalized thecompanyhasaccruedamountsincludinganadditionalaccrualmadeinthesecondquarteroftocoverthese tentativesettlementagreementshoweverthesettlementswillnotresolveallpendingstatelitigationmattersregarding risperdalandsomestatesmayelecttooptoutofthesettlementstotheextentanystatehasaclaimandhasorwill electtooptoutofthesesettlementsthecompanyhasaccruedanamountequaltowhatthatstatewouldreceiveifitwas participatinginthesettlementsamongotherstatesarkansaslouisianaandsouthcarolinaarenotexpectedto participateinthesettlementsasdiscussedbelowbecausethecompanybelievestherearestrongargumentsonappeal inthosecasesthecompanyhasonlyaccruedanamountequaltowhatthesestateswouldreceiveiftheyparticipatedin thesettlements inadditiontheattorneysgeneralofmultiplestatesincludingalaskaarkansaslouisianamassachusettsmississippi montananewmexicosouthcarolinaandutahhavependingactionsagainstjanssenpharmaceuticanowjpiseeking johnsonjohnsonannualreport oneormoreofthefollowingremediesreimbursementofmedicaidorotherpublicfundsforrisperdalprescriptions writtenforofflabelusecompensationfortreatingtheircitizensforallegedadversereactionstorisperdalcivilfines orpenaltiesdamagesforoverpaymentsbythestateandothersviolationsofstateconsumerfraudstatutespunitive damagesorotherreliefrelatingtoallegedunfairbusinesspracticescertainoftheseactionsalsoseekinjunctiverelief relatingtothepromotionofrisperdalinjanuaryjpisettledalawsuitfiledbytheattorneygeneraloftexasin aprilinthelawsuitbroughtbytheattorneygeneralofarkansasthejuryfoundagainstbothjpiandjohnson johnsonandthecourtimposedpenaltiesintheamountofapproximatelybillionjpiandjohnsonjohnsonhave filedanappealandbelievethattheyhavestrongargumentssupportingtheappealinjanuarythesamecourt awardedattorneyfeesofapproximatelymillionthisjudgmentwillalsobeappealed theattorneygeneralofwestvirginiacommencedsuitinagainstjanssenpharmaceuticanowjpibasedon claimsofallegedconsumerfraudastoduragesicaswellasrisperdaljpiwasfoundliableanddamageswere assessedatmillionjpifiledanappealandinnovemberthewestvirginiasupremecourtreversedthetrial courtsdecisionindecembertheattorneygeneralofwestvirginiadismissedthecaseasitrelatedto risperdalwithoutanypaymentthereafterjpisettledthecaseinsofarasitrelatedtoduragesic intheattorneygeneraloflouisianafiledamulticountcomplaintagainstjanssenpharmaceuticanowjpi johnsonjohnsonwaslateraddedasadefendantthecasewastriedinoctobertheissuetriedtothejurywas whetherjohnsonjohnsonorjpihadviolatedthestatesmedicaidfraudacttheactthroughmisrepresentations allegedlymadeinthemailingofanovemberdearhealthcareprofessionalletterregardingrisperdalthejury returnedaverdictthatjpiandjohnsonjohnsonhadviolatedtheactandawardedmillionindamagesthetrial judgesubsequentlyawardedtheattorneygeneralcounselfeesandexpensesintheamountofmillioninaugust aninterlocutoryappellatecourtaffirmedthejudgmentinjanuarythelouisianasupremecourtaccepted johnsonjohnsonandjpisrequestforappealoralargumentontheappealhasbeensetformarch intheofficeofgeneralcounselofthecommonwealthofpennsylvaniafiledalawsuitagainstjanssen pharmaceuticanowjpionamulticountcomplaintrelatedtojanssenpharmaceuticassaleofrisperdaltothe commonwealthsmedicaidprogramthetrialoccurredinjunethetrialjudgedismissedthecaseafterthecloseof theplaintiffsevidencethecommonwealthfiledanappealinaprilandinjulythepennsylvaniaappeals courtupheldthedismissalofthecommonwealthscase intheattorneygeneralofsouthcarolinafiledalawsuitagainstjohnsonjohnsonandjanssenpharmaceutica nowjpionseveralcountsinmarchthematterwastriedonliabilityonlyatwhichtimethelawsuitwaslimitedto claimsofviolationofthesouthcarolinaunfairtradepracticeactincludingamongothersquestionsofwhether johnsonjohnsonorjpiengagedinunfairordeceptiveactsorpracticesintheconductofanytradeorcommerceby distributingthenovemberdearhealthcareprofessionalletterregardingrisperdalorintheiruseofthe productsfdaapprovedlabelthejuryfoundinfavorofjohnsonjohnsonandagainstjpiinjunethecourt awardedcivilpenaltiesofapproximatelymillionjpihasappealedthisjudgmentandthecompanybelievesithas strongargumentssupportingtheappealoralargumentontheappealhasbeensetbeforethesouthcarolinasupreme courtformarch theattorneysgeneralofapproximatelyotherstatesandthedistrictofcolumbiaindicatedaninterestinpursuing similarlitigationagainstjpiandobtainedatollingagreementstayingtherunningofthestatuteoflimitationswhilethey pursuedaninvestigationofjpiregardingpotentialconsumerfraudactionsinconnectionwiththemarketingof risperdalinseptemberjpisettledwithofthestatesandthedistrictofcolumbianonmedicaidclaimsin connectionwiththesalesandmarketingofrisperdalandinvegaforatotalofapproximatelymillionan amountwhichhadbeenpreviouslyaccrued inthecompanysopiniontheultimateresolutionofanyoftheaboverisperdalmattersisnotexpectedtohavea materialadverseeffectonthecompanysfinancialpositionalthoughtheresolutioninanyreportingperiodcouldhavea materialimpactonthecompanysresultsofoperationsandcashflowsforthatperiod omnicare inseptemberjohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekingdocumentsrelatedtothesalesandmarketingofeightdrugstoomnicareincomnicarea managerofpharmaceuticalbenefitsforlongtermcarefacilitiesinapriljohnsonjohnsonandcertainofits pharmaceuticalsubsidiarieswereservedintwocivilquitamcasesassertingclaimsunderthefederalfalseclaimsact andrelatedstatelawclaimsallegingthatthedefendantsprovidedomnicarewithrebatesandotherallegedkickbacks causingomnicaretofilefalseclaimswithmedicaidandothergovernmentprogramsinjanuarythegovernment johnsonjohnsonannualreportintervenedinbothofthesecasesnamingjohnsonjohnsonorthomcneiljanssenpharmaceuticalsincnowjanssen pharmaceuticalsincjpiandjohnsonjohnsonhealthcaresystemsincasdefendantssubsequentlythe commonwealthofmassachusettsvirginiaandkentuckyandthestatesofcaliforniaandindianaintervenedinthe actioninfebruarytheunitedstatesdistrictcourtforthedistrictofmassachusettsdismissedonequitamcase entirelyanddismissedtheothercaseinpartrejectingallegationsthatthedefendantshadviolatedtheirobligationto reportitsbestpricetohealthcareprogramofficialstheclaimsoftheunitedstatesandindividualstatesremain pendinginjunethepartiesweregrantedtheirjointmotiontostaythecasependingresolutionofthepotential settlementdiscussedintherisperdalsectionabove innovemberalawsuitwasfiledbyscottbartzaformeremployeeintheunitedstatesdistrictcourtforthe easterndistrictofpennsylvaniaagainstjohnsonjohnsonandcertainofitspharmaceuticalsubsidiariesthejj defendantsalongwithcodefendantsmckessoncorporationmckessonandomnicareincinfebruarythe plaintifffiledanamendedcomplaintthereafteronthejjdefendantsmotionthecasewastransferredtotheunited statesdistrictcourtforthedistrictofmassachusettswhereitiscurrentlypendingtheamendedcomplaintallegesa varietyofcausesofactionunderthefederalfalseclaimsactandcorrespondingstateandlocalstatutesincludingthat thejjdefendantsengagedinvariousimpropertransactionsthatwereallegedlydesignedtoreportfalseprescription drugpricestothefederalgovernmentinordertoreducethejjdefendantsmedicaidrebateobligationsthecomplaint furtherallegesthatthejjdefendantsimproperlyretaliatedagainsttheplaintiffforhavingraisedtheseallegations internallybartzseeksmultipleformsofreliefincludingdamagesandreinstatementtoapositionwiththesameseniority statusthejjdefendantssubsequentlymovedtodismissthecomplaintinmayinmarchthedistrictcourt dismissedbartzsclaimsunderthefederalfalseclaimsactanddeclinedtoexercisesupplementaljurisdictionover numerousrelatedclaimsunderstatefalseclaimsactstatutesthedistrictcourthoweverdeniedthedismissalmotion withregardtobartzsclaimsthathewasretaliatedagainstinviolationofthefederalfalseclaimsactandinviolationof newjerseysconscientiousemployeeprotectionactinfebruarythepartiesenteredintoasettlementagreement toresolveallofbartzsclaimsandfiledajointmotiontodismissthelawsuitwithprejudicethedistrictcourtgrantedthe motiontodismissallclaims mcneilconsumerhealthcare startinginjunemcneilconsumerhealthcaredivisionofmcneilppcincmcneilconsumerhealthcareand certainaffiliatesincludingjohnsonjohnsonthecompaniesreceivedgrandjurysubpoenasfromtheunitedstates attorneysofficefortheeasterndistrictofpennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvarious productsofmcneilconsumerhealthcareandthefdainspectionsofthefortwashingtonpennsylvaniaandlancaster pennsylvaniamanufacturingfacilitiesaswellascertaindocumentsrelatingtorecallsofasmallnumberofproductsof othersubsidiariesinadditioninfebruarythegovernmentservedmcneilppcincmcneilppcwithacivil investigativedemandseekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationofthefederalfalse claimsactthecompaniesarecooperatingwiththeunitedstatesattorneysofficeinrespondingtothesesubpoenas thecompanieshavealsoreceivedcivilinvestigativedemandsfrommultiplestateattorneysgeneralofficesbroadly relatingtothemcneilrecallissuesthecompaniescontinuetocooperatewiththeseinquiriesinjanuarythe oregonattorneygeneralfiledacivilcomplaintagainstjohnsonjohnsonmcneilppcandmcneilhealthcarellcin statecourtallegingcivilviolationsoftheoregonunlawfultradepracticesactrelatingtoanearlierrecallofamcneilotc productinnovemberthestatecourtgrantedamotionbythecompaniestodismissoregonscomplaintinits entiretywithprejudiceindecemberoregonfiledanoticeofappealinthecourtofappealsofthestateof oregon inmarchtheunitedstatesfiledacomplaintforinjunctivereliefintheunitedstatesdistrictcourtfortheeastern districtofpennsylvaniaagainstmcneilppcandtwoofitsemployeesallegingthatmcneilppcisinviolationoffda regulationsregardingthemanufactureofdrugsatthefacilitiesitoperatesinlancasterpennsylvaniafortwashington pennsylvaniaandlaspiedraspuertoricoonthesamedaythepartiesfiledaconsentdecreeofpermanentinjunction resolvingtheclaimssetforthinthecomplaintthecourtapprovedandenteredtheconsentdecreeonmarch theconsentdecreewhichissubjecttoongoingenforcementbythecourtrequiresmcneilppctotakeenhanced measurestoremediatethethreefacilitiesthefortwashingtonfacilitywhichwasvoluntarilyshutdowninaprilwill remainshutdownuntilathirdpartyconsultantcertifiesthatitsoperationswillbeincompliancewithapplicablelawand thefdaconcurswiththethirdpartycertificationthelancasterandlaspiedrasfacilitiesmaycontinuetomanufacture anddistributedrugsprovidedthatathirdpartyreviewsmanufacturingrecordsforselectedbatchesofdrugsreleased johnsonjohnsonannualreport fromthefacilitiesandcertifiesthatanydeviationsrevieweddonotadverselyaffectthequalityoftheselectedbatches mcneilppcsubmittedaworkplantothefdaforremediationofthelancasterandlaspiedrasfacilitiesandthatplan wasapprovedbythefdainoctoberthirdpartybatchrecordreviewmayceaseifthefdahasstatedthatthe facilitiesappeartobeincompliancewithapplicablelaweachfacilityissubjecttoafiveyearauditperiodbyathirdparty afterthefacilityhasbeendeemedbythefdatobeinapparentcompliancewithapplicablelaw injulysciosincsciosreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekingdocumentsrelatedtothesalesandmarketingofnatrecorinaugustscioswas advisedthattheinvestigationwouldbehandledbytheunitedstatesattorneysofficeforthenortherndistrictof californiainsanfranciscoinfebruarytwoquitamcomplaintswereunsealedintheunitedstatesdistrictcourt forthenortherndistrictofcaliforniaallegingamongotherthingsimproperactivitiesinthepromotionofnatrecorin junetheunitedstatesgovernmentintervenedinoneofthequitamactionsandfiledacomplaintagainstsciosand johnsonjohnsonseekingreliefunderthefederalfalseclaimsactandassertingaclaimofunjustenrichmentin octoberthecriminalmatterwasresolvedthecivilcasehasbeenstayedpendingresolutionofthepotential settlementdiscussedintherisperdalsectionabove injunejohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsrelatingtothemarketingofbiliarystentsbycordiscorporationcordisinfebruarythe governmentinformedcordisthatitwasclosingitsinvestigationinadditioninjanuaryacomplaintwasunsealedin theunitedstatesdistrictcourtforthenortherndistrictoftexasfiledbykevincolquittseekingdamagesagainstcordis andotherpartiesforallegedviolationsofthefederalfalseclaimsactandseveralsimilarstatelawsinconnectionwiththe marketingofbiliarystentstheunitedstatesdepartmentofjusticeandseveralstatesdeclinedtointerveneinjanuary thecourtgrantedcordissmotiontodismisstheclaimsagainstcordiswithprejudiceplaintiffhasappealed inseptembersynthesincsynthesreceivedacivilinvestigativedemandissuedpursuanttothefalseclaimsact fromtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniathedemandsoughtinformation regardingallegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproducts syntheshasproduceddocumentsandinformationinresponsetothedemandandiscooperatingwiththeinquiry inoctobertheeuropeancommissionecannouncedthatitopenedaninvestigationconcerninganagreement betweenjanssencilagbvjanssencilagandsandozbvrelatingtothesupplyoffentanylpatchesinthenetherlands andwhethertheagreementinfringeseuropeancompetitionlawinjanuarytheecissuedastatementof objectionssettingoutfactsregardingapotentialviolationofeuantitrustlawsjanssencilagispreparingaresponseto thestatementofobjections inapriljanssenpharmaceuticalsincjpireceivedaletterrequestingcertaindocumentsfromtheunitedstates departmentofjusticerelatingtothemarketingandpromotionofdoribaxjpihasprovideddocumentsandcontinues tocooperatewiththisgovernmentinquiry inmayacclarentincacclarentreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsrequestingdocumentsbroadlyrelatingtothesalesmarketingandpromotionbyacclarentofrelieva stratusmicroflowspacerproductsacclarentiscooperatingwiththeunitedstatesattorneysofficeinresponding tothesubpoena inaugustdepuyorthopaedicsincdepuyincnowdepuysynthesincdepuysynthesandjohnson johnsonservicesincreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictof massachusettsandthecivildivisionoftheunitedstatesdepartmentofjusticefortheproductionofmaterialsrelatingto theasrxlhipdevicethegovernmenthassincemadeadditionalinformalrequestsfortheproductionofdocumentsas tothedevicethegovernmentisinvestigatingwhetheranypersonorentitysubmittedorcausedtobesubmittedfalse claimsorfalsestatementsaffectingfederalhealthcareprogramsinconnectionwiththemarketinganduseoftheasrxl hipdevicedepuyorthopaedicsincdepuysynthesandjohnsonjohnsonservicesinchavevoluntarilyproduced documentsinresponsetothegovernmentsinformalrequestsandarefullycooperatingwiththegovernmentscivil investigation inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonsubsidiariesjohnsonjohnsonanditssubsidiarieshavesinceenteredintoatollingagreementwith thestatesparticipatinginthemultistateinvestigation johnsonjohnsonannualreportindecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesales andmarketingofuvadexmethoxsalenandtheuvarxtssystemduringtheperiodtothepresentthe unitedstatesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelatetothe investigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpocdandjohnson johnsonretaincertainliabilitiesthatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleoftherakos andhavetakenappropriatestepstoretainpotentiallyrelevantdocumentsandwillcooperatewiththeunitedstates attorneysofficesinvestigationwithrespecttosuchactivity inrecentyearsjohnsonjohnsonhasreceivednumerousrequestsfromavarietyofunitedstatescongressional committeestoproduceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsonto cooperatewiththeseinquiriesbyproducingtherequestedinformation generallitigation startinginjulyfivelawsuitswerefiledinunitedstatesdistrictcourtforthedistrictofnewjerseybyvarious employersandemployeebenefitplansandfundsseekingtorecoveramountstheypaidforrisperdalforplan participantsingeneralplaintiffsallegethatjohnsonjohnsonandcertainofitspharmaceuticalsubsidiariesengagedin offlabelmarketingofrisperdalinviolationofthefederalandnewjerseyricostatutesinadditionplaintiffs assertedvariousstatelawclaimsallofthecaseswereconsolidatedintoonecaseseekingclassactionstatusbutshortly thereafteroneactionwasvoluntarilydismissedindecemberthecourtdismissedtheactionsofthefourremaining plaintiffsinaprilthoseplaintiffsfiledanewconsolidatedclassactionagainstjohnsonjohnsonandjanssenlp nowjanssenpharmaceuticalsincandinmarchthatactionwasdismissedinapriloneofthoseplaintiffs filedanoticeofappealwiththeunitedstatescourtofappealsforthethirdcircuitthatappealwasdismissedinjuly inaprilorthoclinicaldiagnosticsincocdreceivedagrandjurysubpoenafromtheunitedstatesdepartment ofjusticeantitrustdivisionrequestingdocumentsandinformationfortheperiodbeginningseptemberthrough thepresentpertainingtoaninvestigationofallegedviolationsoftheantitrustlawsinthebloodreagentsindustryocd compliedwiththesubpoenainfebruaryocdreceivedaletterfromtheantitrustdivisionindicatingthatithad closeditsinvestigationinnovemberinjunefollowingthepublicannouncementthatocdhadreceiveda grandjurysubpoenamultipleclassactioncomplaintswerefiledagainstocdbydirectpurchasersseekingdamagesfor allegedpricefixingthevariouscaseswereconsolidatedforpretrialpurposesintheunitedstatesdistrictcourtforthe easterndistrictofpennsylvaniaasinrebloodreagentantitrustlitigationinaugustthedistrictcourtgranteda motionfiledbyplaintiffsforclasscertificationocdrequestedinterlocutoryreviewoftheclasscertificationdecisionand inoctobertheappellatecourtgrantedocdspetitionforinterlocutoryreview inaprilaputativeclassactionlawsuitwasfiledintheunitedstatesdistrictcourtforthenortherndistrictof californiabyrepresentativesofnursinghomeresidentsortheirestatesagainstjohnsonjohnsonomnicareinc omnicareandotherunidentifiedcompaniesorindividualsinfebruaryplaintiffsfiledasecondamendedcomplaint assertingthatcertainrebateagreementsbetweenjohnsonjohnsonandomnicareincreasedtheamountofmoneyspent onpharmaceuticalsbythenursinghomeresidentsandviolatedtheshermanactandthecaliforniabusinessprofessions codethesecondamendedcomplaintalsoassertedaclaimofunjustenrichmentplaintiffssoughtmultipleformsof monetaryandinjunctivereliefjohnsonjohnsonmovedtodismissthesecondamendedcomplaintinmarchthe courtgrantedthemotioninitsentiretyinaugustdismissingallclaimsassertedbyplaintiffsinoctoberthe courtdismissedtheactionwithprejudicetheplaintiffsfiledanoticeofappealtotheunitedstatescourtofappealsfor theninthcircuitinnovemberinfebruaryplaintiffsstipulatedtoavoluntarydismissalofthematterwith prejudicepursuanttothetermsofthestipulationtheninthcircuitdismissedthecaseinitsentiretyinmarch startinginmaymultiplecomplaintsseekingclassactioncertificationrelatedtothemcneilrecallshavebeenfiled againstmcneilconsumerhealthcareandcertainaffiliatesincludingjohnsonjohnsonintheunitedstatesdistrictcourt fortheeasterndistrictofpennsylvaniathenortherndistrictofillinoisthecentraldistrictofcaliforniathesoutherndistrict ofohioandtheeasterndistrictofmissouritheseconsumercomplaintsallegegenerallythatpurchasersofvariousmcneil medicinesareowedmonetarydamagesandpenaltiesbecausetheypaidpremiumpricesfordefectivemedicationsrather thanlessexpensivealternativemedicationsallbutonecomplaintseekscertificationofanationwideclassofpurchasersof thesemedicineswhereasonecomplainttheharveycaseseekscertificationofaclassofmotrinibpurchasersin missouriinoctoberthejudicialpanelonmultidistrictlitigationconsolidatedalloftheconsumercomplaintsexcept fortheharveycasewhichwasconsolidatedinmarchintoonelawsuitinremcneilconsumerhealthcareetal johnsonjohnsonannualreport marketingandsalespracticeslitigationforpretrialproceedingsintheunitedstatesdistrictcourtfortheeasterndistrict ofpennsylvaniainjanuarytheplaintiffsinallofthecasesexcepttheharveycasefiledaconsolidatedamendedcivil consumerclassactioncomplaintcacnamingadditionalpartiesandclaimsinjulythecourtgrantedamotionby johnsonjohnsontodismissthecacwithoutprejudicebutpermittedtheplaintiffstofileanamendedcomplaintwithin thirtydaysofthedismissalorderinaugusttheplaintiffsfiledasecondamendedcivilconsumerclassaction complaintsacinjulythecourtgrantedjohnsonjohnsonsmotiontodismissthesacwithprejudice separatelyinseptemberjohnsonjohnsonjohnsonjohnsonincandmcneilconsumerhealthcaredivisionof johnsonjohnsonincreceivedanoticeofcivilclaimfiledbynickfieldinthesupremecourtofbritishcolumbia canadathebccivilclaimthebccivilclaimisaputativeclassactionbroughtonbehalfofpersonswhoresidein britishcolumbiaandwhopurchasedduringtheperiodbetweenseptemberandthepresentoneormore variousmcneilinfantsorchildrensoverthecountermedicinesthatweremanufacturedatthefortwashingtonfacility thebccivilclaimallegesthatthedefendantsviolatedthebcbusinesspracticesandconsumerprotectionactand othercanadianstatutesandcommonlawsbysellingmedicinesthatwereallegedlynotsafeandoreffectiveordidnot complywithcanadiangoodmanufacturingpracticesthebcplaintiffservedtheiraffidavitsinsupportofclass certificationinaprilthedefendantsrespondingaffidavitswereservedinjunethedateforhearingofthe certificationapplicationhasnotyetbeenscheduled inseptemberashareholderronaldmonkfiledalawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyseekingclasscertificationandallegingthatjohnsonjohnsonandcertainindividualsincludingexecutiveofficers andemployeesofjohnsonjohnsonfailedtodisclosethatanumberofmanufacturingfacilitiesfailedtomaintaincurrent goodmanufacturingpracticesandthatasaresultthepriceofthecompanysstockdeclinedsignificantlyplaintiffseeks topursueremediesunderthesecuritiesexchangeactoftorecoverhisallegedeconomiclossesindecember amotionbyjohnsonjohnsontodismisswasgrantedinpartanddeniedinpartplaintiffmovedthecourtto reconsiderpartofthedecemberrulingdefendantsfiledanswerstotheremainingclaimsoftheamended complaintinfebruaryandthecaseisproceedingtodiscoveryinmaythecourtdeniedplaintiffsmotionfor reconsiderationinseptemberplaintifffiledasecondamendedcomplaintandjohnsonjohnsonhasmovedto dismissplaintiffssecondamendedcomplaintinpart inaprilomjpharmaceuticalsincomjprfiledalawsuitagainsttheunitedstatesinunitedstatesdistrictcourt forthedistrictofpuertoricoallegingoverpaymentoffederalincometaxesforthetaxyearsendednovember andnovemberomjprallegesthattheinternalrevenueserviceerroneouslycalculatedomjprstaxcredits undersectionofthetaxcodeomjprfiledamotionforsummaryjudgmentandtheunitedstatesfiledacross motionforsummaryjudgmentinoctoberthecourtgrantedtheunitedstatesmotionforsummaryjudgmentand deniedomjprsmotionforsummaryjudgmentomjprappealedthisdecisionifomjprlosesthislawsuititmayface liabilityforsubsequenttaxyears inaugustanarbitrationpanelruledthatmitsubishitanabepharmacorporationtanabejanssenbiotechincs jbisdistributorofremicadeinjapancouldseektomodifytheproportionofnetsalesrevenuethattanabemust remittojbiinexchangefordistributionrightsandcommercialsupplyofremicadethesupplypricetanabe commencedthearbitrationagainstcentocororthobiotechincnowjbiinpursuanttothepartiesdistribution agreementwhichgrantstanabetherighttodistributeremicadeinjapanandcertainotherpartsofasiajbihas counterclaimedforanincreaseinthesupplypriceahearingwasheldinnovembertodeterminetheappropriate splitofrevenueandthepartiesareawaitingadecision johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation shareholderderivativeactions startinginaprilanumberofshareholderderivativelawsuitswerefiledintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstcertaincurrentandformerdirectorsandofficersofjohnsonjohnsonjohnsonjohnson isnamedasanominaldefendanttheseactionswereconsolidatedinaugustintoonelawsuitinrejohnson johnsonderivativelitigationadditionallyinseptemberanothershareholderderivativelawsuitwasfiledbymichael wolininnewjerseysuperiorcourtagainstcertaincurrentandformerdirectorsandofficersofjohnsonjohnson johnsonjohnsonisnamedasanominaldefendantinthisactionaswellthepartiestothisactionhavestipulatedthatit shallbestayeduntiltheinrejohnsonjohnsonderivativelitigationiscompletelyresolved johnsonjohnsonannualreporttheseshareholderderivativeactionsaresimilarintheirclaimsandcollectivelytheyassertavarietyofallegedbreachesof fiduciarydutiesincludingamongotherthingsthatthedefendantsallegedlyengagedinapprovedoforfailedtoremedy orpreventdefectivemedicaldevicesimproperpharmaceuticalrebatesimproperofflabelmarketingofpharmaceutical andmedicaldeviceproductsviolationsofcurrentgoodmanufacturingpracticeregulationsthatresultedinproductrecalls andthattheyfailedtodisclosetheaforementionedallegedmisconductinthecompanysfilingsunderthesecurities exchangeactofeachcomplaintseeksavarietyofreliefincludingmonetarydamagesandcorporategovernance reformsjohnsonjohnsonmovedtodismisstheseactionsonthegroundsinteraliathattheplaintiffsfailedtomakea demandupontheboardofdirectorsinseptemberinrejohnsonjohnsonderivativelitigationwasdismissed withoutprejudiceandwithleavetofileanamendedcomplaint johnsonjohnsonfiledareportintheinrejohnsonjohnsonderivativelitigationmatterinjulypreparedbya specialcommitteeoftheboardofdirectorswhichinvestigatedtheallegationscontainedinthederivativeactionsandin anumberofshareholderdemandlettersthattheboardreceivedinraisingsimilarissuesthespecialcommittee wasassistedinitsinvestigationbyindependentcounselthespecialcommitteesreportrecommendedithatjohnson johnsonrejecttheshareholderdemandsandtakewhateverstepsarenecessaryorappropriatetosecuredismissalofthe derivativelitigationandiithattheboardofdirectorscreateanewregulatoryandcompliancecommitteechargedwith responsibilityformonitoringandoversightofthecompanyshealthcarecomplianceandqualitycompliancesystems andissuestheboardofdirectorsofjohnsonjohnsonunanimouslyadoptedthespecialcommittees recommendationsandinapriltheboardofdirectorscreatedtheregulatorycompliancegovernmentaffairs committee inaugusttwoshareholderswhohadsubmittedshareholderdemandlettersinfiledshareholderderivative lawsuitsintheunitedstatesdistrictcourtforthedistrictofnewjerseynamingvariouscurrentandformerofficersand directorsasdefendantsandchallengingtheboardsrejectionoftheirdemandsinnovemberthecourt consolidatedthesetwocasesintocopelandvprincejohnsonjohnsonsecuredanextensionoftimetorespondtothe complaint twoadditionalshareholderderivativelawsuitswerefiledinmayintheunitedstatesdistrictcourtforthedistrictof newjerseyandtwoothershareholderderivativelawsuitswerefiledinnewjerseysuperiorcourtinmayand augustallnamingcurrentdirectorsofjohnsonjohnsonasdefendantsandjohnsonjohnsonasthenominal defendantthecomplaintsallegebreachesoffiduciarydutiesrelatedtothecompanyscompliancewiththeforeign corruptpracticesactandparticipationintheunitednationsiraqoilforfoodprogramthatthecompanyhassuffered damagesasaresultofthoseallegedbreachesandthatthedefendantsfailedtodisclosetheallegedmisconductinthe companysfilingsunderthesecuritiesexchangeactofplaintiffsseekmonetarydamagesandthestatecourt plaintiffsalsoseekcorporategovernancereformsthefederallawsuitswereconsolidatedinjulyintoinrejj fcpaderivativeshareholderlitigationandanamendedconsolidatedcomplaintwasfiledinaugustinoctober johnsonjohnsonmovedtodismisstheconsolidatedfederallawsuitonthegroundsthattheplaintiffsfailedto makeademandupontheboardofdirectorstheplaintiffssecuredanextensionoftimetorespondtothemotionthe statelawsuitswereconsolidatedinnovemberintoinrejjshareholderderivativelitigationandaconsolidated complaintwasfiledindecemberinjanuaryjohnsonjohnsonmovedtodismissorstaythestatelawsuits pendingresolutionofthefederallawsuitandmovedtodismissonthegroundthattheplaintiffsfailedtomakeademandon theboardofdirectorsinmaythecourtgrantedamotionbyjohnsonjohnsontostaythestatelawsuitspending resolutionofinrejjfcpaderivativeshareholderlitigation injulythepartiesineachoftheshareholderderivativecasespendinginfederalcourtdiscussedabovespecifically inrejohnsonjohnsonderivativelitigationcopelandvprinceandinrejjfcpaderivativeshareholderlitigation filedastipulationofsettlementtopermanentlyresolvealloftheactionsintheirentiretyinoctoberthesettlement wasapprovedbythecourtinnovemberanoticeofappealwasfiledintheunitedstatescourtofappealsforthe thirdcircuitbyashareholderwhoobjectedtotheapprovalofthesettlementinthedistrictcourtonthegroundsthatthe lawsuitandthesettlementdidnotprovideanybenefittothecompanyandthatplaintiffscounselhadrequestedan excessivefeeaward injunetwoothershareholderswhohadsubmittedashareholderdemandletterinmarchthenewjersey buildinglaborersannuityandthenewjerseybuildinglaborerspensionfundsfiledanadditionalshareholderderivative lawsuitinnewjerseysuperiorcourtnamingvariouscurrentandformerofficersanddirectorsasdefendantsandalso challengingtheboardsrejectionoftheirdemandsthisshareholderderivativelawsuitpurportstoallegethesameclaims thatarethesubjectofthesettlementdescribedabovethepartiestothisactionhadenteredintoaconsentorderstaying theactionpendingfinalapprovalofthesettlementdiscussedaboveinnovembertheplaintiffsagreedtovoluntarily dismisstheaction johnsonjohnsonannualreport inseptembertwoadditionalshareholderderivativelawsuitswerefiledintheunitedstatesdistrictcourtforthe districtofnewjerseybydonovanspamerandthegeorgeleonfamilytrustnamingcurrentdirectorsandoneformer directorofjohnsonjohnsonasdefendantsandjohnsonjohnsonasthenominaldefendanttheselawsuitsallegethat thedefendantsbreachedtheirfiduciarydutiesintheirdecisionswithrespecttothecompensationofthechiefexecutive officerduringtheperiodfromthroughandthatthedefendantsmademisleadingstatementsinthe companysannualproxystatementsbothoftheselawsuitshavebeenvoluntarilydismissedwithoutprejudicebuta similarlawsuitonbehalfofthegeorgeleonfamilytrustwasrefiledinjulythatlawsuitseeksavarietyofrelief includingmonetarydamagesinjunctivereliefandcorporategovernancereformstheabovesettlementdoesnotresolve thesepotentialclaimstheboardofdirectorsevaluationoftheseallegationsisongoing restructuring incordiscorporationasubsidiaryofjohnsonjohnsonannouncedthediscontinuationofitsclinicaldevelopment programforthenevosirolimuselutingcoronarystentandcessationofthemanufactureandmarketingofcypher andcypherselectplussirolimuselutingcoronarystentsbytheendofthecompanywillfocusonother cardiovasculartherapieswheresignificantpatientneedsexist asaresultoftheabovementionedrestructuringplanannouncedbycordiscorporationthecompanyrecorded millioninrelatedpretaxchargesofwhichapproximatelymillionofthepretaxrestructuringchargesrequirecash paymentsthemillionofrestructuringchargesconsistsofassetwriteoffsofmillionandmillionrelated toleaseholdandcontractobligationsandotherexpensesthemillionofassetwriteoffsrelatetopropertyplantand equipmentofmillionintangibleassetsofmillionandinventoryofmillionrecordedincostofproducts soldthecordisrestructuringprogramhasbeensubstantiallycompletedtherestructuringchargewasrecordedinthe medicaldevicesanddiagnosticssegment johnsonjohnsonannualreportreport independent registered public accounting firm totheshareholdersandboardofdirectorsofjohnsonjohnson inouropiniontheaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearnings statementsofcomprehensiveincomestatementsofequityandstatementsofcashflowspresentfairlyinallmaterial respectsthefinancialpositionofjohnsonjohnsonanditssubsidiariesatdecemberandjanuaryand theresultsoftheiroperationsandtheircashflowsforeachofthethreeyearsintheperiodendeddecemberin conformitywithaccountingprinciplesgenerallyacceptedintheunitedstatesofamericaalsoinouropinionthe companymaintainedinallmaterialrespectseffectiveinternalcontroloverfinancialreportingasofdecember basedoncriteriaestablishedininternalcontrolintegratedframeworkissuedbythecommitteeofsponsoring organizationsofthetreadwaycommissioncosothecompanysmanagementisresponsibleforthesefinancial statementsformaintainingeffectiveinternalcontroloverfinancialreportingandforitsassessmentoftheeffectivenessof internalcontroloverfinancialreportingincludedintheaccompanyingmanagementsreportoninternalcontrolover financialreportingourresponsibilityistoexpressopinionsonthesefinancialstatementsandonthecompanysinternal controloverfinancialreportingbasedonourintegratedauditsweconductedourauditsinaccordancewiththestandards ofthepubliccompanyaccountingoversightboardunitedstatesthosestandardsrequirethatweplanandperform theauditstoobtainreasonableassuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementand whethereffectiveinternalcontroloverfinancialreportingwasmaintainedinallmaterialrespectsourauditsofthefinancial statementsincludedexaminingonatestbasisevidencesupportingtheamountsanddisclosuresinthefinancial statementsassessingtheaccountingprinciplesusedandsignificantestimatesmadebymanagementandevaluatingthe overallfinancialstatementpresentationourauditofinternalcontroloverfinancialreportingincludedobtainingan understandingofinternalcontroloverfinancialreportingassessingtheriskthatamaterialweaknessexistsandtesting andevaluatingthedesignandoperatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalso includedperformingsuchotherproceduresasweconsiderednecessaryinthecircumstanceswebelievethatouraudits provideareasonablebasisforouropinions acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statements becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate asdescribedinmanagementsreportoninternalcontroloverfinancialreportingmanagementhasexcludedsynthes incfromitsassessmentofinternalcontroloverfinancialreportingasofdecemberbecauseitwasacquiredby thecompanyinapurchasebusinesscombinationduringwehavealsoexcludedsynthesincfromourauditof internalcontroloverfinancialreportingsynthesincisawhollyownedsubsidiarywhosetotalassetsandtotalrevenues representapproximatelyandrespectivelyoftherelatedconsolidatedfinancialstatementamountsasofandfor theyearendeddecember pricewaterhousecoopersllp newyorknewyork february johnsonjohnsonannualreport managements report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciples internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofdecemberinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframeworkthese criteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunicationand monitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignandoperating effectivenessofitsinternalcontrolsoverfinancialreporting thecompanyacquiredsynthesincanditsconsolidatedsubsidiariessynthesinjunesynthestotalassets whichwereprimarilyintangibleassetsandgoodwillandtotalrevenuesrepresentedapproximatelyand respectivelyoftherelatedconsolidatedfinancialstatementsasofandfortheperiodendeddecemberasthe acquisitionoccurredinjuneandsyntheswaspreviouslynotsubjecttotherequirementsundersectionofthe sarbanesoxleyactofthescopeofthecompanysassessmentofthedesignandeffectivenessofinternalcontrol overfinancialreportingforthefiscalyearexcludedsynthesthisexclusionisinaccordancewiththesecsgeneral guidancethatanassessmentofarecentlyacquiredbusinessmaybeomittedfromthescopeintheyearofacquisition basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof decemberthecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofdecemberhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappears herein alexgorsky dominicjcaruso chairmanboardofdirectors vicepresidentfinance chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreportsummary operations statistical data dollarsinmillionsexceptpershare amounts salestocustomersus salestocustomersinternational totalsales costofproductssold sellingmarketingandadministrativeexpenses researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalized otherincomeexpensenet restructuring earningsbeforeprovisionfortaxesonincome provisionfortaxesonincome netearnings addnetlossattributabletononcontrollinginterest netearningsattributableto johnsonjohnson percentofsalestocustomers dilutednetearningspershareofcommonstock percentreturnonaverageshareholdersequity percentincreasedecreaseover previousyear salestocustomers dilutednetearningspershare supplementarybalancesheetdata propertyplantandequipmentnet additionstopropertyplantandequipment totalassets longtermdebt operatingcashflow commonstockinformation dividendspaidpershare shareholdersequitypershare marketpricepershareyearendclose averagesharesoutstandingmillions basic diluted employeesthousands attributabletojohnsonjohnson johnsonjohnsonannualreport shareholder return performance graphs setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingdecemberagainstthecumulativetotalreturnofthestandard poorsstockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipment indexthegraphsandtablesassumethatwasinvestedondecemberanddecemberineachof thecompanyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexand thestandardpoorshealthcareequipmentindexandthatalldividendswerereinvested year cumulative total shareholder return johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex year cumulative total shareholder return johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreportboard directors senior management alexgorsky alexgorsky chairmanboardofdirectors chiefexecutiveofficer chairmanexecutivecommittee marysuecoleman charleseaustin presidentuniversityofmichigan vicepresidentglobalsupplychain jamesgcullen dominicjcaruso retiredpresidentandchiefoperatingofficer vicepresidentfinance bellatlanticcorporation chieffinancialofficer ianeldavis memberexecutivecommittee senioradvisorapaxpartnersformerchairmanand douglaskchia worldwidemanagingdirectormckinseycompany corporatesecretary assistantgeneralcounsel michaelmejohns professoremoryschoolofmedicineandrollins stephenjcosgrove schoolofpublichealthchancellorandexecutive corporatecontroller vicepresidentofhealthaffairsemeritusemory chiefaccountingofficer university joaquinduato susanllindquist worldwidechairmanpharmaceuticalsgroup memberandformerdirectorwhiteheadinstitutefor petermfasolo biomedicalresearchprofessorofbiology vicepresidentglobalhumanresources massachusettsinstituteoftechnology memberexecutivecommittee annemmulcahy karenalicitra formerchairmanandchiefexecutiveofficer worldwidechairmanglobalmedicalsolutionsgroup xeroxcorporation michelorsinger leofmullin worldwidechairmanglobalorthopaedicsgroup retiredchairmanandchiefexecutiveofficer deltaairlinesinc johnapapa treasurer williamdperez senioradvisorgreenhillcoincretiredpresident sandraepeterson andchiefexecutiveofficerwmwrigleyjrcompany groupworldwidechairman memberexecutivecommittee charlesprince retiredchairmanandchiefexecutiveofficer garyjpruden citigroupinc worldwidechairmanglobalsurgerygroup michaelesneed davidsatcher vicepresidentglobalcorporateaffairs directorcenterofexcellenceonhealthdisparities directorsatcherhealthleadershipinstituteand paulusstoffels poussaintsatchercosbychairinmentalhealth chiefscientificofficer morehouseschoolofmedicine worldwidechairmanpharmaceuticalsgroup memberexecutivecommittee aeugenewashington vicechancellorofhealthsciencesdeanofthedavid michaelhullmann geffenschoolofmedicineattheuniversityofcalifornia vicepresidentgeneralcounsel losangelesuclachiefexecutiveofficerofthe memberexecutivecommittee uclahealthsystem jessejwu ronaldawilliams worldwidechairmanconsumergroup formerchairmanandchiefexecutiveofficer aetnaincprincipaloffice commonstock johnsonjohnsonontheweb onejohnsonjohnsonplaza listedonnewyorkstockexchange ourwebsitewwwjnjcom newbrunswicknewjersey stocksymboljnj shareholderrelationscontact ourcompanyblogwwwjnjbtwcom annualmeeting douglaskchia theannualmeetingofshareholderswilltake corporatesecretary ourhistoryblogwwwkilmerhousecom placeonthursdayaprilatthe hyattregencyhoteltwoalbanystreetnew investorrelationscontact wwwfacebookcomjnj brunswicknewjerseythemeetingwill conveneatamallshareholdersasofthe louisemehrotra recorddateoffebruaryarecordially vicepresidentinvestorrelations wwwtwittercomjnjcares invitedtoattendaformalnoticeofannual wwwtwittercomjnjnews meetingproxystatementandproxyhave wwwyoutubecomuserjnjhealth beensenttoshareholders transferagentandregistrar wwwyoutubecomuserjnjenntv corporategovernance questionsregardingstockholdingscertificate wwwlinkedincomcompany copiesofourannualreporton replacementtransferdividendsandaddress johnsonjohnson formkquarterlyreportsonformq changesshouldbedirectedto andcurrentreportsonformktothe computersharetrustcompanyna securitiesandexchangecommissionproxy royallstreet toviewthejohnsonjohnsonannualreport statementandthisannualreportare cantonma pleasegotowwwannualreportjnjcom availableonlineatwwwinvestorjnjcom orscanthisqrcode secfilingscfmortoshareholderswithout outsidetheus chargeuponwrittenrequesttothesecretary wwwcomputersharecom atourprincipaladdressorbycalling dividendreinvestmentplan theplanallowsforfullorpartialdividend inadditiononthecorporategovernance reinvestmentandadditionalmonthlycash sectionofourwebsitewwwinvestorjnjcom investmentsuptoperyearin shareholderscanviewourrestatedcertificate johnsonjohnsoncommonstockwithout ofincorporationbylawsprinciplesof brokeragecommissionsorservicechargeson corporategovernancechartersoftheaudit stockpurchasesifyouareinterestedin committeecompensationbenefits participatingintheplanandneedan committeenominatingcorporate authorizationformandormoreinformation governancecommitteeregulatory pleasecallcomputersharetrustcompany compliancegovernmentaffairs naator committeeandsciencetechnology outsidetheus sustainabilitycommitteepolicyonbusiness conductforemployeescodeofbusiness hearingimpaired conductethicsformembersoftheboard shareholderswhohaveinquiriesregarding ofdirectorsandexecutiveofficersandother stockrelatedmatterscancommunicate corporategovernancematerialscopiesof directlywithcomputersharetrustcompany thesedocumentsareavailabletoshareholders naviaatelecommunicationsdevicetdd withoutchargeuponwrittenrequesttothe thetelephonenumberforthisserviceis secretaryatourprincipaladdress oroutsidethe us undersectionofthesarbanesoxleyact wearerequiredtofilecertificationssignedby electronicdeliverynotification thechiefexecutiveofficerandthechief theproxystatementandourannual financialofficerasexhibitstoourformk reportareavailableonourwebsiteat orformqforeachfiscalyearorquarter wwwinvestorjnjcomannualreportscfm inadditionwearerequiredtosubmita insteadofreceivingpapercopiesofnextyears certificationsignedbythechiefexecutive proxystatementandannualreportbymail officertothenewyorkstockexchange youcanelecttoreceiveanemailmessagethat withindaysfollowingtheannualmeeting willprovidealinktothosedocumentsonthe ofshareholderscopiesofthecertifications internetshareholderswhoholdtheirshares filedforpreviousyearsarepostedonthe intheirownnamemayenrollintheelectronic corporategovernancesectionofourwebsite proxyandannualreportaccessservicefor andfuturecertificationswillbeposted futureannualmeetingsofshareholders promptlyuponfiling onlineatwwwcomputersharenacomgreen shareholdersthatholdtheirsharesinstreet namethatisinthenameofabankbroker thejohnsonjohnsonannualreportcontainsmanyof orotherholderofrecordwhowishtoenroll thevaluabletrademarksandtradenamesownedandused forelectronicaccessmayregisterforonline bythejohnsonjohnsonfamilyofcompaniesinthe deliveryofmaterialsbygoingto unitedstatesandinternationallytodistinguishproducts enrollicsdelivercomjnj andservicesofoutstandingquality johnsonjohnson shareholder informationour credo believe first responsibility istothe doctorsnurses patients tomothers fathers others whouse products services inmeeting needs everything wedo must high quality must constantly strivetoreduce costsin order maintain reasonable prices customersorders must serviced promptly accurately suppliers distributors must opportunity tomake afair profit responsible toour employees men women whowork withusthroughout worldeveryone must considered asan individual must respect dignity recognize merit must asense security jobscompensation must fair adequate working conditions clean orderly safewe must mindful waystohelp employees fulfill family responsibilities employees must feel free tomake suggestions complaints must equal opportunity employment development advancement thosequalified must provide competent management actions must justand ethical responsible tothe communities welive workand tothe world community aswell must good citizens support good worksand charities bear fair share taxeswe must encourage civic improvements better health education must maintain good order property weare privileged touse protecting environment natural resources final responsibility istoour stockholders businessmust make sound profit must experiment withnew ideas research must carried oninnovative programs developed mistakes paid fornew equipment must purchased new facilities provided new products launched reserves must created toprovide adverse timeswhen weoperate according tothese principles stockholders realize afair return onejohnsonjohnsonplazanewbrunswicknewjersey